var title_f7_52_8000="Severe right PIE";
var content_f7_52_8000=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe right-sided pulmonary interstitial emphysema in a neonate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 283px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note massive hyperinflation of right lung with herniation across midline.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gerardo Cabrera-Meza, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_52_8000=[""].join("\n");
var outline_f7_52_8000=null;
var title_f7_52_8001="Barnidipine: International drug information";
var content_f7_52_8001=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Barnidipine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cypress (NL);",
"     </li>",
"     <li>",
"      Dilacor (AR);",
"     </li>",
"     <li>",
"      Hypoca (JP, TH);",
"     </li>",
"     <li>",
"      Libradin (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F2677644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Barnidipine Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2677645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker, Dihydropyridine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2677646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2677648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Hypertension: 5-20 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2677649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule, sustained release: 10 mg, 15 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10472 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-113.53.254.124-160CFEADCC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_52_8001=[""].join("\n");
var outline_f7_52_8001=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369732\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677644\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677645\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677646\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677648\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821216\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677649\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10472\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10472|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_52_8002="p65 subunit of NF kB in RA";
var content_f7_52_8002=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    p65 subunit of nuclear factor-kappa B (NF-kB) in rheumatoid synovium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Localization of p65 subunit of nuclear factor-kappa B by immunohistochemistry. Brown staining indicates nuclei containing this subunit. These are present in the synovial lining layer and in the sublining (hematoxylin counterstain).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ellen M Gravallese, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_52_8002=[""].join("\n");
var outline_f7_52_8002=null;
var title_f7_52_8003="Patient information: Vaccines and pregnancy (The Basics)";
var content_f7_52_8003=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/57/27538\">",
"         Patient information: Chickenpox (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/47/33522\">",
"         Patient information: Flu (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/22/5475\">",
"         Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/42/27298\">",
"         Patient information: Staying healthy when you travel (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/61/33746\">",
"         Patient information: Tdap vaccine (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/48/12035\">",
"         Patient information: Vaccines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/4/23619\">",
"         Patient information: Vaccines for adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/44/21187\">",
"         Patient information: Vaccines for travel (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/25/39318\">",
"         Patient information: Adult vaccines (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/52/43843\">",
"         Patient information: Avoiding infections in pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/12/39105\">",
"         Patient information: Influenza prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/7/17522\">",
"         Patient information: Vaccination during pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vaccines and pregnancy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/vaccines-and-pregnancy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1643010845\">",
"      <span class=\"h1\">",
"       What are vaccines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Vaccines are treatments that can prevent certain serious or deadly infections. They work by preparing the body to fight the germs that cause the infections. Vaccines usually come in shots, but some come in nose sprays or medicines that people swallow. Vaccines are also called &ldquo;vaccinations&rdquo; or &ldquo;immunizations.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1643010852\">",
"      <span class=\"h1\">",
"       Why should I get vaccinated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Getting vaccinated can help keep you from getting certain serious infections. It&rsquo;s important to be vaccinated even if you don&rsquo;t become pregnant. But if you are pregnant and get certain infections, you can have problems during your pregnancy. Being vaccinated can also help keep your baby from getting sick.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1643010859\">",
"      <span class=\"h1\">",
"       What should I know about vaccines if I am planning to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are planning to get pregnant, you should make sure that your vaccines are up to date. This means that you have gotten all of the vaccines that your doctor or nurse recommends. If you are not sure if you got all of your vaccines, your doctor or nurse might do a blood test to check.",
"     </p>",
"     <p>",
"      It&rsquo;s especially important that women be up to date with their vaccines for measles, mumps, rubella, and chickenpox before they get pregnant. That&rsquo;s because vaccines to prevent these infections cannot be given to pregnant women. If women who have not been vaccinated do get these infections during pregnancy, they can have problems. Problems can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Having a baby with a birth defect",
"       </li>",
"       <li>",
"        Giving birth too early",
"       </li>",
"       <li>",
"        Having a miscarriage &ndash; A miscarriage is when a pregnancy ends on its own.",
"       </li>",
"       <li>",
"        Spreading the infection to the baby",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Women who need the measles, mumps, rubella, or chickenpox vaccines should get them at least 1 month before getting pregnant.",
"     </p>",
"     <p>",
"      It&rsquo;s also important that women be up to date with a vaccine called the HPV vaccine before they get pregnant. The HPV vaccine is another vaccine that cannot be given to pregnant women.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1643010866\">",
"      <span class=\"h1\">",
"       Do I need the chickenpox vaccine if I had chickenpox infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. If you had chickenpox infection in the past, you do not need to get the vaccine. People who have had chickenpox can&rsquo;t get the illness again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1643010873\">",
"      <span class=\"h1\">",
"       Which vaccines are safe to get during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some vaccines are safe to get during pregnancy. These include vaccines to prevent:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Influenza (flu) &ndash; All adults should get the flu vaccine each year. But it&rsquo;s especially important for pregnant women to get the flu vaccine. That&rsquo;s because pregnant women tend get more severely ill with the flu than people who are not pregnant. The flu vaccine can keep a woman from getting sick. It can also keep a baby from getting the flu during the first few months of life.",
"       </li>",
"       <li>",
"        Tetanus, diphtheria, and pertussis &ndash; Tetanus causes the muscles to work abnormally. Diphtheria can cause a thick covering in the back of the throat that can lead to breathing problems. Pertussis, also known as &ldquo;whooping cough,&rdquo; causes a severe cough. All pregnant women should get the tetanus, diphtheria, and pertussis vaccine at 27 to 36 weeks of pregnancy, even if they got it before.",
"       </li>",
"       <li>",
"        Some women might get other vaccines while they are pregnant. For example, women might need certain vaccines if they have other medical conditions or plan to travel to another country.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1643010880\">",
"      <span class=\"h1\">",
"       How many vaccine doses do I need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Each vaccine is different. Some vaccines work after just 1 dose. Others need 2 or more doses to prevent an infection. Most vaccines take a few weeks to work.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1643010887\">",
"      <span class=\"h1\">",
"       What side effects can vaccines cause?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Often, vaccines cause no side effects. When they do cause side effects, they can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Redness, mild swelling, or soreness where the shot was given",
"       </li>",
"       <li>",
"        A mild fever",
"       </li>",
"       <li>",
"        A mild rash",
"       </li>",
"       <li>",
"        Headache or body aches",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Vaccines also sometimes cause more serious side effects, such as severe allergic reactions. But serious side effects are rare.",
"     </p>",
"     <p>",
"      Ask your doctor or nurse what side effects to expect each time you get a vaccine. If you have a reaction or a problem after a vaccine, let him or her know.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1643010894\">",
"      <span class=\"h1\">",
"       What if I have an egg allergy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have an egg allergy, let your doctor or nurse know. Some vaccines have egg in them because of how they are made. Your doctor or nurse will tell you which vaccines are safe to get.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1643010901\">",
"      <span class=\"h1\">",
"       What if I am pregnant and never got the measles, mumps, rubella, or chickenpox vaccines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are pregnant and never got these vaccines and never had these infections, you should avoid people with these infections.",
"     </p>",
"     <p>",
"      If you find out that someone around you has chickenpox, call your doctor or nurse as soon as possible. He or she can give you a medicine to reduce your chances of getting it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1643010908\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=see_link\">",
"       Patient information: Vaccines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=see_link\">",
"       Patient information: Flu (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=see_link\">",
"       Patient information: Vaccines for adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/44/21187?source=see_link\">",
"       Patient information: Vaccines for travel (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/57/27538?source=see_link\">",
"       Patient information: Chickenpox (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=see_link\">",
"       Patient information: Staying healthy when you travel (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/22/5475?source=see_link\">",
"       Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/61/33746?source=see_link\">",
"       Patient information: Tdap vaccine (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/7/17522?source=see_link\">",
"       Patient information: Vaccination during pregnancy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/52/43843?source=see_link\">",
"       Patient information: Avoiding infections in pregnancy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"       Patient information: Adult vaccines (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=see_link\">",
"       Patient information: Influenza prevention (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/52/8003?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15748 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-A7B55BFC08-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_52_8003=[""].join("\n");
var outline_f7_52_8003=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1643010845\">",
"      What are vaccines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1643010852\">",
"      Why should I get vaccinated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1643010859\">",
"      What should I know about vaccines if I am planning to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1643010866\">",
"      Do I need the chickenpox vaccine if I had chickenpox infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1643010873\">",
"      Which vaccines are safe to get during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1643010880\">",
"      How many vaccine doses do I need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1643010887\">",
"      What side effects can vaccines cause?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1643010894\">",
"      What if I have an egg allergy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1643010901\">",
"      What if I am pregnant and never got the measles, mumps, rubella, or chickenpox vaccines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1643010908\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/52/43843?source=related_link\">",
"      Patient information: Avoiding infections in pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/57/27538?source=related_link\">",
"      Patient information: Chickenpox (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/22/5475?source=related_link\">",
"      Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=related_link\">",
"      Patient information: Influenza prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=related_link\">",
"      Patient information: Staying healthy when you travel (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/61/33746?source=related_link\">",
"      Patient information: Tdap vaccine (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/7/17522?source=related_link\">",
"      Patient information: Vaccination during pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/44/21187?source=related_link\">",
"      Patient information: Vaccines for travel (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_52_8004="High-grade glioma in adults";
var content_f7_52_8004=[" <h1 id=\"patTopicTitle\">",
"  Patient information: High-grade glioma in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/52/8004/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/52/8004/contributors\" id=\"au4436\">",
"       Tracy Batchelor, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/52/8004/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/52/8004/contributors\" id=\"se4309\">",
"       Patrick Y Wen, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/52/8004/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/52/8004/contributors\" id=\"de8764\">",
"       April F Eichler, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?7/52/8004?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HIGH-GRADE GLIOMA OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Primary brain tumors are cancers that originate in the brain. These tumors are very different from secondary brain tumors, which originally developed elsewhere in the body and spread (metastasized) to the brain.",
"    </p>",
"    <p>",
"     Primary brain tumors develop from glial cells. Glial cells provide the structural backbone of the brain and support the function of the neurons (nerve cells), which are responsible for thought, sensation, muscle control, and coordination.",
"    </p>",
"    <p>",
"     This article will discuss the symptoms, diagnosis, and treatment of high-grade (ie, malignant) gliomas, the largest subset of brain gliomas. Primary low-grade gliomas are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/42/36515?source=see_link\">",
"      \"Patient information: Primary low-grade glioma in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CLASSIFICATION OF PRIMARY BRAIN TUMORS",
"     </span>",
"    </p>",
"    <p>",
"     Primary brain tumors are tumors that classified according to their appearance under the microscope. Gliomas are classified into four grades (I, II, III and IV), and the treatment and prognosis depend upon the tumor grade [",
"     <a class=\"abstract\" href=\"UTD.htm?7/52/8004/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Grade I or II tumors are termed low-grade gliomas. The term malignant or high-grade glioma refers to tumors that are classified as:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Grade III (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, anaplastic ependymoma)",
"      </li>",
"      <li>",
"       Grade IV (glioblastoma)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      HIGH-GRADE GLIOMA SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Gliomas cause symptoms by invading (growing) into",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     creating pressure in nearby normal brain tissue. The most common symptoms include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Cognitive symptoms like memory loss, personality change, confusion, speech problems",
"      </li>",
"      <li>",
"       Headache",
"      </li>",
"      <li>",
"       Seizures &mdash; Seizures occur in more than one-half of patients with grade III gliomas and about one-fourth of patients with grade IV gliomas. Seizures are caused by disorganized electrical activity in the brain. Medications can help to control seizures.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Other common symptoms of brain tumors include muscle weakness, visual symptoms, and changes in sensation.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      HIGH-GRADE GLIOMA TESTS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Imaging studies",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your healthcare provider is concerned about your symptoms,",
"     <span class=\"nowrap\">",
"      s/he",
"     </span>",
"     may recommend a scan of the brain. This can be done using MRI or CT. Both tests provide a very detailed image of the brain. However, a CT or MRI cannot determine for sure if a mass is a cancerous tumor.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;The only way to determine the type of tumor with certainty is for a neurosurgeon to remove a piece of the tumor (biopsy), usually during surgery. A pathologist will then examine the biopsy under a microscope.",
"    </p>",
"    <p>",
"     However, a biopsy may be done without surgery; this approach is preferred if the tumor is located within a critical area of the brain or if you are too sick for surgery. In these circumstances, a procedure called a stereotactic needle biopsy is used to take a sample of the tumor by inserting a needle through the skull into the brain itself.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      HIGH-GRADE GLIOMA INITIAL TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of a high-grade glioma includes measures to relieve symptoms and eliminate or reduce the tumor. This may include surgery, radiation,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     chemotherapy. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link\">",
"      \"Adjuvant chemotherapy for malignant gliomas\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4712?source=see_link\">",
"      \"Adjuvant radiation therapy for malignant gliomas\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=see_link\">",
"      \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Everyone with high grade glioma is encouraged to participate in a clinical trial, if possible. (See",
"     <a class=\"local\" href=\"#H20\">",
"      'Clinical trials'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Symptom management",
"     </span>",
"     &nbsp;&mdash;&nbsp;Seizures and swelling in the brain (cerebral edema) can cause serious symptoms that may be life-threatening. Although treatment of the tumor may eventually alleviate these symptoms, treatments aimed at controlling the symptoms may be required:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Seizures &mdash; Anti-seizure medications can usually control seizures caused by a brain tumor.",
"      </li>",
"      <li>",
"       Cerebral edema &mdash; Cerebral edema is swelling in the brain. It is treated with glucocorticoids (also called steroids), most commonly dexamethasone (Brand name: Decadron&reg;).",
"       <br/>",
"       <br/>",
"       To minimize side effects, the dose of dexamethasone is decreased gradually to the lowest level that controls symptoms.",
"      </li>",
"      <li>",
"       Hydrocephalus &mdash; Cerebrospinal fluid normally surrounds and cushions the brain. Hydrocephalus occurs when the flow of cerebrospinal fluid is blocked, which increases pressure within the brain. Treatment may require surgery to place a tube in the skull (called a shunt) to bypass the blockage and lower the pressure within the brain.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;The initial treatment of high-grade glioma usually involves removing as much of the tumor as possible with surgery. The amount of tumor that can be removed is determined by the tumor's size and location, and by how much normal brain will be damaged as a result of surgery. The standard approach is to remove as much of the tumor as possible, while sparing areas of the normal brain that control critical functions such as speech or balance.",
"    </p>",
"    <p>",
"     Unfortunately, high-grade gliomas always have microscopic tumor cells that grow beyond the edge of the tumor. As a result, the tumor eventually regrows and few people with high-grade gliomas are cured with surgery alone. Radiation is typically recommended after surgery to kill any remaining tumor cells.",
"    </p>",
"    <p>",
"     Surgery may not be possible if the tumor is located in a part of the brain that controls critical functions or if you are in poor health. In these circumstances, radiation may be recommended as an alternative to surgery (see",
"     <a class=\"local\" href=\"#H10\">",
"      'Radiation'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Radiation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Even when the entire tumor appears to have been removed, almost all high-grade gliomas eventually come back. This is because tumor cells have grown into the surrounding normal brain. Radiation therapy uses high energy x-rays to kill cancer cells and is usually recommended following surgery to kill remaining tumor cells. This treatment is called adjuvant radiation. Radiation can help to delay a recurrence of the tumor, allowing you to live longer.",
"    </p>",
"    <p>",
"     Radiation is generally given as a series of once daily treatments (called fractions) over several weeks. This approach helps to kill the greatest number of tumor cells and minimize side effects on normal brain cells. The area where the radiation is delivered (called the radiation field) is carefully calculated to include the smallest possible amount of normal brain as possible.",
"    </p>",
"    <p>",
"     Most brain tumors that grow back are within 2 cm (one inch) of the original tumor location. As a result, radiation is usually delivered to the \"involved field\" (the original area of the tumor plus a small margin) rather than the whole brain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radiation may kill normal brain cells as well as tumor cells, although tumor cells are somewhat more sensitive to the radiation. Damage to normal brain cells is often subtle, affecting mental sharpness and the ability to think and perform complex tasks (called cognitive impairment). Cognitive impairment tends to be more severe with larger radiation fields, tends to worsen over time, and is more of a problem in people who survive for several years after radiation treatments to the brain. It is not always possible to know if cognitive impairment is caused by radiation or a recurrence of the high-grade glioma.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy refers to the use of medicines to stop or slow the growth of cancer cells. Chemotherapy works by interfering with the ability of rapidly growing cells (like cancer cells) to divide. Because most of an adult's normal cells are not actively growing, they are not affected by chemotherapy, with the exception of bone marrow (where blood cells are produced), the hair, and the lining of the gastrointestinal tract. Effects of chemotherapy on these and other normal tissues cause side effects during treatment.",
"    </p>",
"    <p>",
"     When used in combination with radiation therapy and surgery, chemotherapy may improve survival and quality of life in some patients with high-grade gliomas. The drug that are most widely used for high-grade glioma include temozolomide (Brand name: Temodar&reg;).",
"    </p>",
"    <p>",
"     Temozolomide is usually taken by mouth for five consecutive days every four weeks. It is usually taken during and after radiation therapy.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      TREATMENT AFTER RECURRENCE",
"     </span>",
"    </p>",
"    <p>",
"     High-grade gliomas recur or regrow in most patients, usually within one to two years following diagnosis. There is controversy about the potential benefits of treatment when the tumor recurs [",
"     <a class=\"abstract\" href=\"UTD.htm?7/52/8004/abstract/2\">",
"      2",
"     </a>",
"     ]. If you decide to undergo treatment, you must consider the risks of treatment as well as the potential impact on your quality of life.",
"    </p>",
"    <p>",
"     Treatment of a high-grade glioma that has recurred does not always improve survival compared to supportive care alone (ie, treatments to ease pain and other symptoms) (see",
"     <a class=\"local\" href=\"#H19\">",
"      'End of life care'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     You may benefit from retreatment if you have:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Good overall health",
"      </li>",
"      <li>",
"       A smaller amount of tumor present",
"      </li>",
"      <li>",
"       A longer interval (eg, one year versus less than one year) between your original treatment and the recurrence",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Options available for retreatment include surgery, various forms of radiation, and chemotherapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is not clear which people with recurrent high grade-glioma will benefit from surgery. The most important factor that predicts a longer survival after reoperation is your overall health. Other factors that increase the chances of prolonged survival include a younger age, a long interval between operations (eg, one year or more), and removing a larger amount of tissue with the second surgery.",
"    </p>",
"    <p>",
"     The average survival of people who undergo surgery for recurrent grade IV gliomas ranges from 14 to 36 weeks. It is somewhat longer for patients with grade III tumors (56 to 88 weeks). Placing a biodegradable chemotherapy wafer (Gliadel&reg;) during surgery may prolong survival further. In one study, people who had a Gliadel&reg; wafer placed had a significantly longer median survival (31 versus 23 weeks) compared to people who had a placebo wafer [",
"     <a class=\"abstract\" href=\"UTD.htm?7/52/8004/abstract/3\">",
"      3",
"     </a>",
"     ]. However, there are potential side effects from the wafer including brain swelling and infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Radiation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although there are exceptions, giving additional radiation is not usually possible in people with high-grade glioma recurrence because of the high risk of damage to normal brain tissue. Special techniques, such as stereotactic radiosurgery or brachytherapy, may permit additional radiation to be directly selectively to the tumor. However, there is no proof that these radiation treatments improve survival or provide any benefit to the patient compared to supportive care alone.",
"    </p>",
"    <p>",
"     Stereotactic radiosurgery involves the use of three-dimensional planning and specialized techniques to precisely deliver a dose of radiation to a small target in a single or limited number of treatments. The treatment does not involve surgery. By carefully focusing the radiation on the area containing the tumor, side effects to normal brain can be minimized. The initial radiosurgery system was called the gamma knife; however, other systems have been developed for this same purpose.",
"    </p>",
"    <p>",
"     With interstitial brachytherapy, a radioactive substance (called \"radioactive seeds\") is placed directly into the area of tumor recurrence at the time of reoperation, where it slowly releases radiation that is active only over a very short distance. Although brachytherapy may be effective, it can cause serious side effects (see",
"     <a class=\"local\" href=\"#H11\">",
"      'Side effects'",
"     </a>",
"     above).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy is not as effective for recurrent high-grade gliomas as it is for treatment when newly diagnosed. Oral CCNU (lomustine) is an option in this situation. Enrollment in a clinical trial is often recommended, when possible.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Bevacizumab",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bevacizumab (Brand name: Avastin&reg;) is an antibody (a type of protein) that targets a different protein called vascular endothelial growth factor (VEGF). VEGF causes a growing cancer to develop its own blood supply, which is essential for the tumor to grow and spread. Bevacizumab disrupts the process of new blood vessel formation, thereby depriving the tumor of its supply of nutrients.",
"    </p>",
"    <p>",
"     Bevacizumab may be used alone or in combination with chemotherapy. However, bevacizumab can cause some serious side effects, including high blood pressure, bleeding, stroke, and infection.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      OLIGODENDROGLIOMAS",
"     </span>",
"    </p>",
"    <p>",
"     Oligodendrogliomas represent an important subset of grade III gliomas and account for about 10 percent of all primary gliomas [",
"     <a class=\"abstract\" href=\"UTD.htm?7/52/8004/abstract/4\">",
"      4",
"     </a>",
"     ]. These tumors have lost parts of chromosomes and have a very high likelihood of responding to treatment, allowing the person a longer survival.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      END OF LIFE CARE",
"     </span>",
"    </p>",
"    <p>",
"     In many people with high-grade glioma, the disease cannot be cured. Deciding when to stop treating the cancer can be difficult and should involve the patient, family, friends, and the healthcare team.",
"    </p>",
"    <p>",
"     Ending cancer treatment does not mean ending care for the patient. Hospice care is frequently recommended when a person is unlikely to live longer than six months. Hospice care involves treatment of all aspects of a patient and family's needs, including the physical (eg, pain relief), psychological, social, and spiritual aspects of suffering. This care may be given at home or in a nursing home or hospice facility and usually involves multiple care providers, including a physician, registered nurse, nursing aide, a chaplain or religious leader, a social worker, and volunteers.",
"    </p>",
"    <p>",
"     These providers work together to meet the patient and family's needs and significantly reduce their suffering. For more information about hospice, see",
"     <a class=\"external\" href=\"file://www.hospicenet.org/\">",
"      www.hospicenet.org",
"     </a>",
"     . (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=see_link\">",
"      \"Hospice: Philosophy of care and appropriate utilization in the United States\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating high-grade gliomas requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask for more information about clinical trials, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/learning/\">",
"        www.cancer.gov/clinicaltrials/learning/",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/\">",
"        www.cancer.gov/clinicaltrials/",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"        file://clinicaltrials.gov/",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413263157\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2530846174\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/48/9986?source=see_link\">",
"      Patient information: Brain cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/34/6690?source=see_link\">",
"      Patient information: Astrocytoma (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/28/22978?source=see_link\">",
"      Patient information: Glioblastoma (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2530846191\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/42/36515?source=see_link\">",
"      Patient information: Primary low-grade glioma in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/39/30327?source=see_link\">",
"      Anticoagulant and antiplatelet therapy in patients with brain tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=see_link\">",
"      Classification of gliomas",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=see_link\">",
"      Clinical manifestations and initial surgical approach to patients with malignant gliomas",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2071?source=see_link\">",
"      Diagnosis and classification of low-grade gliomas",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1832?source=see_link\">",
"      Diffuse pontine glioma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15161?source=see_link\">",
"      Ependymoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=see_link\">",
"      Experimental treatment approaches for malignant gliomas",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40585?source=see_link\">",
"      Focal brainstem glioma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44568?source=see_link\">",
"      Management of low-grade glioma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18697?source=see_link\">",
"      Seizures in patients with primary and metastatic brain tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/16/39176?source=see_link\">",
"      Optic pathway glioma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14169?source=see_link\">",
"      Pathogenesis and biology of malignant gliomas",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link\">",
"      Adjuvant chemotherapy for malignant gliomas",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4712?source=see_link\">",
"      Adjuvant radiation therapy for malignant gliomas",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=see_link\">",
"      Hospice: Philosophy of care and appropriate utilization in the United States",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/pdq/treatment/adultbrain/Patient\">",
"      www.cancer.gov/cancertopics/pdq/treatment/adultbrain/Patient",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.com/\">",
"      www.nccn.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-ACS-2345",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Brain Tumor Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.abta.org/\">",
"      www.abta.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Brain Tumor Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.braintumor.org/\">",
"      www.braintumor.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Patient Support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://cancer.about.com/forum\">",
"      file://cancer.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?7/52/8004/abstract/1-9\">",
"      1-9",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 3, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?7/52/8004?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Pathology and genetics of tumours of the nervous system. In: World Health Organization Classification of Tumours of the Nervous System, Editorial and Consensus Conference Working Group, Kleihues, P, Cavenee, WK (Eds), IARC Press, Lyon, France 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8004/abstract/2\">",
"      Hau P, Baumgart U, Pfeifer K, et al. Salvage therapy in patients with glioblastoma: is there any benefit? Cancer 2003; 98:2678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8004/abstract/3\">",
"      Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995; 345:1008.",
"     </a>",
"    </li>",
"    <li>",
"     Statistical Report: Primary Brain Tumors in the United States, 1997-2001. Central Brain Tumor Registry of the United States; 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8004/abstract/5\">",
"      Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005; 293:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8004/abstract/6\">",
"      Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8004/abstract/7\">",
"      Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8004/abstract/8\">",
"      Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003; 5:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8004/abstract/9\">",
"      Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f7_52_8004=[""].join("\n");
var outline_f7_52_8004=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HIGH-GRADE GLIOMA OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CLASSIFICATION OF PRIMARY BRAIN TUMORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           HIGH-GRADE GLIOMA SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           HIGH-GRADE GLIOMA TESTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           HIGH-GRADE GLIOMA INITIAL TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           TREATMENT AFTER RECURRENCE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           OLIGODENDROGLIOMAS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           END OF LIFE CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f7_52_8005="Leukocyte infiltration COPD";
var content_f7_52_8005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leukocyte infiltration in COPD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 169px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph showing leukocyte infiltration in a small airway of a smoker with severe COPD (A); and that of smoker with a mild COPD (B). Immunostaining with monoclonal antibody anti-CD45.&nbsp;Leukocytes are stained in red. Original magnification: X400.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Turato G, Zuin R Miniati M et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002;166:105. Copyright &copy; 2002 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_52_8005=[""].join("\n");
var outline_f7_52_8005=null;
var title_f7_52_8006="Atypical nevi size";
var content_f7_52_8006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atypical nevi size",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atypical nevus with size greater than 6 mm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_52_8006=[""].join("\n");
var outline_f7_52_8006=null;
var title_f7_52_8007="Duodenojejunal rotation";
var content_f7_52_8007=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Normal rotation of the duodenojejunal loop",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A. The midgut forms a slight bend ventrally. B. The duodenojejunal junction rotates 90 degrees counterclockwise (to the right of the superior mesentery artery [SMA]). C. The duodenojejunal junction continues to rotate counterclockwise around the SMA (now 180 degrees from its original position). D. In its final position the duodenojejunal junction has rotated 270 degrees and lies to the left of the SMA.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_52_8007=[""].join("\n");
var outline_f7_52_8007=null;
var title_f7_52_8008="Stereotactic radiosurgery I";
var content_f7_52_8008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F64369%7EENDO%2F76201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F64369%7EENDO%2F76201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stereotactic radiosurgery for Cushing's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal section CT image through the sella turcica and anterior pituitary gland of a patient with Cushing's disease. The brown areas represent brain or other tissue; the black areas represent cerebrospinal fluid (eg, the upper center vertical space is the third ventricle) or air-filled sinuses (eg, the space just below center is the sphenoid sinus); the white areas represent bone (eg, the highest points represent the clinoid processes). A computer-assisted stereotactic \"photon knife\" treatment plan is superimposed on the CT image; it employs two isocenters of 15 Gy radiation delivered by a linear accelerator, one in each half of the anterior pituitary. Each concentric circle is an isorad 1 Gy less than the next inner circle. The optic chiasm will be exposed to less than 8 cGy of radiation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David N Orth, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stereotactic radiosurgery for Cushing's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial section CT image through the sella turcica and pituitary gland of the patient shown in the previous figure. The magnification of the image is considerably greater; the anterior aspect of the image is at the top. The brown areas represent brain or other tissue; the black areas represent air-filled sinuses (eg, the space above and to the left of center is the sphenoid sinus, and the optic foramina are visible angling anterolaterally toward each upper corner of the image); the white areas represent bone (eg, the band below the pituitary gland, which has been artificially colored red and outlined in black, represent the posterior clinoid processes). A computer-assisted stereotactic \"photon knife\" treatment plan is superimposed on the CT image; it employs two isocenters of 15 Gy radiation delivered by a linear accelerator, one in each half of the anterior pituitary. Each concentric circle is an isorad 1 Gy less than the next inner circle. The cavernous sinuses will receive about 8 cGy of radiation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_52_8008=[""].join("\n");
var outline_f7_52_8008=null;
var title_f7_52_8009="Bipolar disorder in adults: Treating major depression with second-generation antipsychotics";
var content_f7_52_8009=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bipolar disorder in adults: Treating major depression with second-generation antipsychotics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/52/8009/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/52/8009/contributors\">",
"     William V Bobo, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/52/8009/contributors\">",
"     Richard C. Shelton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/52/8009/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/52/8009/contributors\">",
"     Paul Keck, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/52/8009/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/52/8009/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/52/8009/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H36032236\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although manic, hypomanic, and mixed episodes are diagnostic hallmarks for bipolar disorder, depressive episodes predominate the lifetime course of illness and result in greater disability and risk of suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Bipolar major depression is often treated with antidepressants, but their use is controversial because these drugs may not be effective and may cause switches from depression to mania as well as rapid cycling. Other drugs that are widely used for bipolar depression include second-generation antipsychotics [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the efficacy, safety, and tolerability of second-generation antipsychotics for bipolar major depression. Choosing a medication regimen for bipolar major depression, mania, mixed episodes, hypomania, and the maintenance treatment of bipolar disorder are discussed separately, as is the efficacy and safety of antidepressants for bipolar major depression:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44088?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=see_link\">",
"       \"Bipolar disorder in adults: Maintenance treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37417?source=see_link\">",
"       \"Bipolar disorder in adults: Treating major depression with antidepressants\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1837115\">",
"    <span class=\"h1\">",
"     DEFINITION OF BIPOLAR DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is a mood disorder that is characterized by episodes of mania (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"UTD.htm?3/53/3932\">",
"     table 1",
"    </a>",
"    ), hypomania (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"UTD.htm?22/39/23164\">",
"     table 2",
"    </a>",
"    ), and major depression (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"     table 3",
"    </a>",
"    ), as well as mixed episodes (major depression concurrent with mania) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/4\">",
"     4",
"    </a>",
"    ]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic and mixed episodes, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic and mixed episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36032348\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For outpatients with bipolar major depression and no comorbid substance use disorders, randomized trials have established the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. By contrast, multiple trials have found no benefit in using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Other second-generation antipsychotics that may possibly be helpful include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/56/2951?source=see_link\">",
"     asenapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/1/15383?source=see_link\">",
"     lurasidone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , but their benefit has yet to be established. (See",
"    <a class=\"local\" href=\"#H5519998\">",
"     'Other second-generation antipsychotics'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, second-generation antipsychotics are often used as monotherapy or in combination with other drugs for mania, as well maintenance treatment of patients with bipolar disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=see_link\">",
"     \"Bipolar disorder in adults: Maintenance treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7300681\">",
"    <span class=\"h2\">",
"     Quetiapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     Quetiapine",
"    </a>",
"    monotherapy is efficacious for bipolar major depression, based upon multiple meta-analyses of randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/5,11\">",
"     5,11",
"    </a>",
"    ]. As an example, one meta-analysis of five homogeneous trials (3057 patients treated for eight weeks) compared quetiapine with placebo (limited use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    and hypnotics was allowed for the first three to four weeks); the primary findings were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Remission occurred in more patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      than placebo (61 versus 42 percent)",
"     </li>",
"     <li>",
"      Reduction of anxiety symptoms was greater with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"     </li>",
"     <li>",
"      Remission was comparable for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      300 mg per day and 600 mg per day",
"     </li>",
"     <li>",
"      Improvement in quality of life (satisfaction) was superior with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      than placebo",
"     </li>",
"     <li>",
"      Remission rates were lower for patients with more severe depressive episodes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, meta-analyses of the same five trials found that discontinuation of treatment because of side effects occurred in more patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    than placebo (24 versus 6 percent), and was greater for quetiapine 600 mg per day than 300 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. Adverse effects that occurred more often with quetiapine than placebo included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sedation",
"     </li>",
"     <li>",
"      Weight gain",
"     </li>",
"     <li>",
"      Dry mouth",
"     </li>",
"     <li>",
"      Headache",
"     </li>",
"     <li>",
"      Dizziness",
"     </li>",
"     <li>",
"      Nausea",
"     </li>",
"     <li>",
"      Constipation",
"     </li>",
"     <li>",
"      Extrapyramidal symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information about",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    side effects (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80747 \" href=\"UTD.htm?22/2/22571\">",
"     table 5",
"    </a>",
"    ) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link&amp;anchor=H76524693#H76524693\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Quetiapine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7300807\">",
"    <span class=\"h3\">",
"     Bipolar II major depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials for bipolar disorder often exclude patients with bipolar II disorder or combine them with bipolar I patients in the analyses. However, several trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    monotherapy included bipolar II patients with major depression and found that the drug was effective for this subgroup:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two randomized trials, each lasting eight weeks, compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      (300 or 600 mg at bedtime) with placebo in patients with bipolar major depression [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/12\">",
"       12",
"      </a>",
"      ]. A pooled analysis of the subgroup of 321 patients with bipolar II depression found that remission was greater with quetiapine 300 or 600",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      compared with placebo (39 and 38 versus 20 percent). This was consistent with the finding that both doses of quetiapine were superior in the total sample of bipolar patients [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/13\">",
"       13",
"      </a>",
"      ]. Among patients with bipolar II depression, discontinuation of treatment due to adverse effects of quetiapine 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and 600",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and placebo were 16, 23, and 2 percent; common side effects of quetiapine included dry mouth, sedation, fatigue, and dizziness.",
"     </li>",
"     <li>",
"      An eight week randomized trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      (300 or 600 mg at bedtime) with placebo in patients with bipolar major depression [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/14\">",
"       14",
"      </a>",
"      ]. In the subgroup of 208 patients with bipolar II disorder, symptoms improved more with both doses of quetiapine than placebo; this was consistent with the finding that quetiapine was superior in patients with bipolar I disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86357398\">",
"    <span class=\"h3\">",
"     Compared with other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although head to head randomized trials seem to suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    monotherapy is superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    monotherapy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    monotherapy for bipolar major depression, the comparative benefit of quetiapine is not clear due to methodologic problems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One eight week trial assigned patients to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      300 mg per day (N = 255), quetiapine 600 mg per day (N = 263), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      (target serum concentration 0.6 to 1.2",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      [0.6 to 1.2",
"      <span class=\"nowrap\">",
"       mmol/L];",
"      </span>",
"      N = 136) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/15\">",
"       15",
"      </a>",
"      ]. Although symptoms improved more with either dose of quetiapine than with lithium, the study was underpowered for lithium [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/16\">",
"       16",
"      </a>",
"      ]. In addition, the mean serum concentration of lithium was 0.61",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      (0.61",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and more than a third of the patients treated with lithium had a median serum concentration &lt;0.6",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      (&lt;0.6",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      &nbsp;",
"     </li>",
"     <li>",
"      One eight week trial assigned patients to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      300 mg per day (N = 229), quetiapine 600 mg per day (N = 232), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      20 mg per day (N = 118) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/14\">",
"       14",
"      </a>",
"      ]. Although symptoms improved more with either dose of quetiapine than with paroxetine, the study was underpowered for paroxetine. In addition, the paroxetine dose was at the low end of the dose range that is usually used to treat major depression (",
"      <a class=\"graphic graphic_table graphicRef53818 \" href=\"UTD.htm?24/43/25278\">",
"       table 6",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173197880\">",
"    <span class=\"h2\">",
"     Olanzapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with bipolar major depression, randomized trials have demonstrated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    monotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One six week trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      (5 to 20 mg per day) with placebo in 514 patients; use of concomitant medication was not reported. Remission occurred in more patients who received olanzapine than placebo (38 versus 29 percent), and discontinuation of treatment due to adverse effects was comparable (9 and 8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One eight week trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      (5 to 20 mg per day) with placebo in 706 patients; benzodiazepines and anticholinergic drugs were allowed as well. Remission occurred in more patients who received olanzapine than placebo (33 versus 25 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/6\">",
"       6",
"      </a>",
"      ]. In the subgroup (N = 311) with comorbid anxiety symptoms, remission occurred more often with olanzapine. However, in the entire sample (N = 706), discontinuation of treatment due to adverse effects occurred in more patients who received olanzapine than placebo (9 versus 5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     Olanzapine",
"    </a>",
"    can cause serious weight gain and may also cause diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. In the randomized trials that compared olanzapine with placebo in patients with bipolar major depression, the following adverse effects occurred more often with olanzapine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sedation",
"     </li>",
"     <li>",
"      Weight gain",
"     </li>",
"     <li>",
"      Increased appetite",
"     </li>",
"     <li>",
"      Dry mouth",
"     </li>",
"     <li>",
"      Weakness",
"     </li>",
"     <li>",
"      Hypercholesterolemia",
"     </li>",
"     <li>",
"      Hypertriglyceridemia",
"     </li>",
"     <li>",
"      Hyperglycemia",
"     </li>",
"     <li>",
"      Alanine aminotransferase abnormally high",
"     </li>",
"     <li>",
"      Aspartate aminotransferase abnormally high",
"     </li>",
"     <li>",
"      Gamma glutamyl transpeptidase abnormally high",
"     </li>",
"     <li>",
"      Hyperprolactinemia",
"     </li>",
"     <li>",
"      Neutropenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information about",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    side effects (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80747 \" href=\"UTD.htm?22/2/22571\">",
"     table 5",
"    </a>",
"    ) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link&amp;anchor=H76524686#H76524686\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Olanzapine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173197887\">",
"    <span class=\"h3\">",
"     Olanzapine plus fluoxetine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    can help patients with bipolar major depression. In one eight-week trial that compared olanzapine plus fluoxetine (6 and 25, 6 and 50, or 12 and 50 mg per day), olanzapine monotherapy (5 to 20 mg per day), and placebo in 833 patients, remission occurred in more patients who received olanzapine plus fluoxetine than olanzapine alone or placebo (49 versus 33 and 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/6\">",
"     6",
"    </a>",
"    ]. However, side effects of the combination included weight gain, increased appetite, dry mouth, weakness, and diarrhea. Additional information about the efficacy of olanzapine plus fluoxetine is discussed separately, as is the risk of switching from depression to mania. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37417?source=see_link\">",
"     \"Bipolar disorder in adults: Treating major depression with antidepressants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    monotherapy (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80747 \" href=\"UTD.htm?22/2/22571\">",
"     table 5",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    monotherapy (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 7",
"    </a>",
"    ) are discussed elsewhere. (See",
"    <a class=\"local\" href=\"#H173197880\">",
"     'Olanzapine'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5519998\">",
"    <span class=\"h2\">",
"     Other second-generation antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low quality evidence (eg, indirect outcome, lack of placebo or other control, or small sample), as well as unpublished studies, suggests that monotherapy with other second-generation antipsychotics may possibly be useful for treating bipolar major depression:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/56/2951?source=see_link\">",
"       Asenapine",
"      </a>",
"      &ndash; A pooled analysis of two randomized trials, each lasting three weeks, compared asenapine (5 or 10 mg twice per day) with placebo in a subgroup of 173 patients with mixed episodes (major depression concurrent with mania) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/20\">",
"       20",
"      </a>",
"      ]. Remission occurred in more patients treated with asenapine than placebo (45 versus 24 percent); this was consistent with the finding that asenapine was superior in the total sample of patients with mania or mixed episodes. However, among patients with mixed episodes, sedation, dizziness, extrapyramidal symptoms, and weight gain occurred more often with asenapine than placebo.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       Clozapine",
"      </a>",
"      &ndash; A retrospective observational study of 326 patients treated with adjunctive clozapine (mean dose 307 mg per day) for up to two years found that the number of hospitalizations and number of days in the hospital were lower during clozapine treatment than the same period of time immediately prior to use of clozapine [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/1/15383?source=see_link\">",
"       Lurasidone",
"      </a>",
"      &ndash; Unpublished, six week randomized trials have found the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one trial, response (reduction of baseline symptoms &ge;50 percent) occurred in more patients who received monotherapy with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/1/15383?source=see_link\">",
"       lurasidone",
"      </a>",
"      20 to 60 mg per day or lurasidone 80 to 120 mg per day, compared with placebo (53 and 51 versus 30 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/22\">",
"       22",
"      </a>",
"      ]. In addition, discontinuation of treatment due to adverse effects was comparable for the three groups (7 and 6 and 6 percent).",
"     </li>",
"     <li>",
"      In the second trial, patients resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      or divalproex monotherapy received adjunctive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/1/15383?source=see_link\">",
"       lurasidone",
"      </a>",
"      or placebo; improvement was greater with lurasidone [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       Risperidone",
"      </a>",
"      &ndash; One trial enrolled 30 patients with an incomplete response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      and randomly assigned the patients to receive adjunctive risperidone,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      , or risperidone plus paroxetine [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/24\">",
"       24",
"      </a>",
"      ]. All three groups improved. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The side effects (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80747 \" href=\"UTD.htm?22/2/22571\">",
"     table 5",
"    </a>",
"    ) of these drugs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36032278\">",
"    <span class=\"h2\">",
"     Drugs with little to no benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with bipolar major depression, multiple randomized trials indicate that there is little to no benefit in using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    : &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"       Aripiprazole",
"      </a>",
"      &ndash; Two eight-week trials compared aripiprazole (5 to 30 mg per day) with placebo in a total of 749 patients; a pooled analysis found that the benefits of aripiprazole and placebo were comparable [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"       Ziprasidone",
"      </a>",
"      &ndash; Two six-week trials compared ziprasidone (20 to 80 mg twice daily) with placebo in a total of 856 patients; in each trial, ziprasidone demonstrated no advantage [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/10,25\">",
"       10,25",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36032292\">",
"    <span class=\"h2\">",
"     Rapid cycling bipolar disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of second-generation antipsychotics to treat bipolar major depression in rapid cycling patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42216?source=see_link&amp;anchor=H92694034#H92694034\">",
"     \"Rapid cycling bipolar disorder in adults: Treatment of major depression\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2229622\">",
"    <span class=\"h2\">",
"     Geriatric bipolar disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of second-generation antipsychotics to treat bipolar major depression in geriatric patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16330?source=see_link&amp;anchor=H361190789#H361190789\">",
"     \"Geriatric bipolar disorder: Acute treatment\", section on 'First-line treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36032356\">",
"    <span class=\"h1\">",
"     SAFETY AND TOLERABILITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259519902\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects associated with second-generation antipsychotics include weight gain, hyperglycemia, type 2 diabetes mellitus, hyperlipidemia, sedation, hyperprolactinemia, neuroleptic malignant syndrome, orthostatic hypotension, sudden death, and an increased risk of mortality when used to treat psychiatric symptoms associated with dementia in elderly patients (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80747 \" href=\"UTD.htm?22/2/22571\">",
"     table 5",
"    </a>",
"    ). Second-generation antipsychotics can also cause extrapyramidal symptoms and tardive dyskinesia, but at rates lower than first-generation drugs. These side effects and their management are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"     \"Causes of hyperprolactinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/40/27269?source=see_link\">",
"     \"Tardive dyskinesia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34952?source=see_link\">",
"     \"Tardive dyskinesia: Prevention and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General principles regarding the safety and tolerability of second-generation antipsychotics in bipolar major depression include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with bipolar depression may be more sensitive to side effects than patients with mania [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The risk of extrapyramidal side effects and tardive dyskinesia is thought to be higher in bipolar disorder than schizophrenia [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Treatment emergent mania does not occur in patients who are treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/6-8,30\">",
"       6-8,30",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, adverse effects can lead to poor adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259517724\">",
"    <span class=\"h3\">",
"     Metabolic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of metabolic side effects (eg, weight gain, hyperlipidemia, and hyperglycemia) is increased with some second-generation antipsychotics [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/32\">",
"     32",
"    </a>",
"    ]; this is important given the increased risk of metabolic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/33\">",
"     33",
"    </a>",
"    ] as well as cardiovascular morbidity and mortality in patients with bipolar disorder relative to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Although most studies of second-generation antipsychotics and metabolic effects involve schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/32\">",
"     32",
"    </a>",
"    ], comparable effects have been found in bipolar disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/5,30,37,38\">",
"     5,30,37,38",
"    </a>",
"    ]. Among second-generation antipsychotics, the greatest risk for metabolic effects is with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/39\">",
"     39",
"    </a>",
"    ]. The risk of clinically significant weight gain for olanzapine monotherapy and olanzapine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    appears to be comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/6,40\">",
"     6,40",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/1/15383?source=see_link\">",
"     Lurasidone",
"    </a>",
"    does not cause short-term weight gain, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/56/2951?source=see_link\">",
"     asenapine",
"    </a>",
"    does [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to initiating treatment with second-generation antipsychotics, we ask patients about their personal and family history of obesity, diabetes, dyslipidemia, hypertension, cardiovascular disease, and family history of sudden cardiac death [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259518705\">",
"    <span class=\"h3\">",
"     Sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with bipolar major depression,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    often cause somnolence that leads to discontinuation of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an eight week randomized trial that compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      with placebo in 706 patients, discontinuation of treatment due to adverse effects occurred in more patients treated with olanzapine than placebo (9 versus 5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/6\">",
"       6",
"      </a>",
"      ]. Among patients who discontinued olanzapine because of side effects, the most frequent cause was sedation.",
"     </li>",
"     <li>",
"      A meta-analysis of five randomized trials (2477 patients treated for eight weeks) that compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      with placebo found that discontinuation of treatment due to somnolence was nearly five times more likely in patients who received quetiapine [",
"      <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173197509\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar patients who are treated with second-generation antipsychotics should be assessed for [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8009/abstract/39,42\">",
"     39,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Metabolic side effects at baseline and periodically thereafter (",
"      <a class=\"graphic graphic_table graphicRef74435 \" href=\"UTD.htm?25/17/25884\">",
"       table 8",
"      </a>",
"      ) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extrapyramidal symptoms at baseline and subsequently at every visit. Patients should also be monitored for tardive dyskinesia at baseline, quarterly in the first year, and annually thereafter, using the Abnormal Involuntary Movement Scale (AIMS) (",
"      <a class=\"graphic graphic_form graphicRef51103 \" href=\"UTD.htm?43/13/44243\">",
"       form 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Orthostatic hypotension at baseline and periodically thereafter",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolactin elevation at baseline and periodically thereafter",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patients may need to be monitored for QT prolongation. Additional information about assessing patients for metabolic side effects, extrapyramidal symptoms, orthostasis, hyperprolactinemia, and QT prolongation is discussed further in the context of schizophrenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36032399\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Medications regimens for bipolar patients are selected according to the phase of illness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44088?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=see_link\">",
"       \"Bipolar disorder in adults: Maintenance treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"      monotherapy is efficacious for short term treatment of bipolar major depression; however the drug can cause sedation, weight gain, dry mouth, headache, dizziness, nausea, constipation, and extrapyramidal symptoms. (See",
"      <a class=\"local\" href=\"#H7300681\">",
"       'Quetiapine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"      monotherapy is efficacious for short term treatment of bipolar major depression; however, the drug can cause serious weight gain and may also cause diabetes mellitus. Other adverse effects include sedation, increased appetite, dry mouth, weakness, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, abnormally high liver functions tests, hyperprolactinemia, and neutropenia. (See",
"      <a class=\"local\" href=\"#H173197880\">",
"       'Olanzapine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      is efficacious for short term treatment of bipolar major depression; however, the combination can cause weight gain, increased appetite, dry mouth, weakness, and diarrhea. (See",
"      <a class=\"local\" href=\"#H173197887\">",
"       'Olanzapine plus fluoxetine'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Other second-generation antipsychotics that may possibly be useful for treating bipolar major depression include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/56/2951?source=see_link\">",
"       asenapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/1/15383?source=see_link\">",
"       lurasidone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H5519998\">",
"       'Other second-generation antipsychotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with bipolar major depression, there is little to no benefit in using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"       ziprasidone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H36032278\">",
"       'Drugs with little to no benefit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Side effects associated with second-generation antipsychotics include weight gain, hyperglycemia, type 2 diabetes mellitus, hyperlipidemia, sedation, hyperprolactinemia, extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, orthostatic hypotension, sudden death, and an increased risk of mortality when used to treat psychiatric symptoms associated with dementia in elderly patients (",
"      <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef80747 \" href=\"UTD.htm?22/2/22571\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H259519902\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among second-generation antipsychotics, the greatest risk for metabolic effects (eg, weight gain, hyperlipidemia, and hyperglycemia) is with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      , followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"       table 4",
"      </a>",
"      ). The risk of clinically significant weight gain appears to be comparable for olanzapine monotherapy and olanzapine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/1/15383?source=see_link\">",
"       Lurasidone",
"      </a>",
"      does not cause short-term weight gain, whereas",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/56/2951?source=see_link\">",
"       asenapine",
"      </a>",
"      does. (See",
"      <a class=\"local\" href=\"#H259517724\">",
"       'Metabolic effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with bipolar major depression,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      often cause somnolence that leads to discontinuation of treatment. (See",
"      <a class=\"local\" href=\"#H259518705\">",
"       'Sedation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bipolar patients who are treated with second-generation antipsychotics should be monitored for metabolic side effects (",
"      <a class=\"graphic graphic_table graphicRef74435 \" href=\"UTD.htm?25/17/25884\">",
"       table 8",
"      </a>",
"      ), extrapyramidal symptoms, tardive dyskinesia (",
"      <a class=\"graphic graphic_form graphicRef51103 \" href=\"UTD.htm?43/13/44243\">",
"       form 1",
"      </a>",
"      ), orthostatic hypotension, and prolactin elevation. In addition, patients may need to be monitored for QT prolongation. (See",
"      <a class=\"local\" href=\"#H173197509\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/1\">",
"      Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/2\">",
"      Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/3\">",
"      Greil W, H&auml;berle A, Haueis P, et al. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J Affect Disord 2012; 136:534.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/5\">",
"      De Fruyt J, Deschepper E, Audenaert K, et al. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol 2012; 26:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/6\">",
"      Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/7\">",
"      Chiesa A, Chierzi F, De Ronchi D, Serretti A. Quetiapine for bipolar depression: a systematic review and meta-analysis. Int Clin Psychopharmacol 2012; 27:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/8\">",
"      Tohen M, McDonnell DP, Case M, et al. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry 2012; 201:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/9\">",
"      Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008; 28:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/10\">",
"      Lombardo I, Sachs G, Kolluri S, et al. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J Clin Psychopharmacol 2012; 32:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/11\">",
"      Vieta E, Locklear J, G&uuml;nther O, et al. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. J Clin Psychopharmacol 2010; 30:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/12\">",
"      Suppes T, Hirschfeld RM, Vieta E, et al. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 2008; 9:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/13\">",
"      Weisler RH, Calabrese JR, Thase ME, et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008; 69:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/14\">",
"      McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/15\">",
"      Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010; 71:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/16\">",
"      Grunze HC. Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression. Evid Based Ment Health 2010; 13:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/17\">",
"      Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004; 161:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/18\">",
"      Fernandez-Egea E, Miller B, Garcia-Rizo C, et al. Metabolic effects of olanzapine in patients with newly diagnosed psychosis. J Clin Psychopharmacol 2011; 31:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/19\">",
"      Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry 2010; 23:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/20\">",
"      Azorin JM, Sapin C, Weiller E. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. J Affect Disord 2013; 145:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/21\">",
"      Nielsen J, Kane JM, Correll CU. Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disord 2012; 14:863.",
"     </a>",
"    </li>",
"    <li>",
"     Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy for the treatment of bipolar depression: results of a 6-week, double-blind, placebo-controlled study. Poster presented at the 165th Annual Meeting of the American Psychiatric Association, May 5-9, 2012 (Philadelphia, PA).",
"    </li>",
"    <li>",
"     Loebel A, Cucchiaro J, Silva R, et al. Lurasidone adjunctive to lithium or valproate for the treatment of bipolar depression: results of a 6-week, double-blind, placebo-controlled study. Poster presented at the 165th Annual Meeting of the American Psychiatric Association, May 5-9, 2012 (Philadelphia, PA).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/24\">",
"      Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry 2004; 65:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/25\">",
"      Sachs GS, Ice KS, Chappell PB, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/26\">",
"      Wang Z, Kemp DE, Chan PK, et al. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder. Int J Neuropsychopharmacol 2011; 14:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/27\">",
"      Gao K, Ganocy SJ, Gajwani P, et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 2008; 69:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/28\">",
"      Keck PE Jr, McElroy SL, Strakowski SM, Soutullo CA. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000; 61 Suppl 4:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/29\">",
"      Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008; 28:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/30\">",
"      Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry 2007; 7:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/31\">",
"      Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/32\">",
"      Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/33\">",
"      Vancampfort D, Vansteelandt K, Correll CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013; 170:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/34\">",
"      Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry 2011; 23:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/35\">",
"      Goldstein BI, Fagiolini A, Houck P, Kupfer DJ. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord 2009; 11:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/36\">",
"      Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/37\">",
"      Torrent C, Amann B, S&aacute;nchez-Moreno J, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand 2008; 118:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/38\">",
"      Gao K, Kemp DE, Fein E, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 2011; 72:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/39\">",
"      American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/40\">",
"      Tamayo JM, Sutton VK, Mattei MA, et al. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. J Clin Psychopharmacol 2009; 29:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/41\">",
"      De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 2012; 26:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8009/abstract/42\">",
"      Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16693 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_52_8009=[""].join("\n");
var outline_f7_52_8009=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36032399\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36032236\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1837115\">",
"      DEFINITION OF BIPOLAR DISORDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36032348\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7300681\">",
"      Quetiapine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7300807\">",
"      - Bipolar II major depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86357398\">",
"      - Compared with other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173197880\">",
"      Olanzapine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H173197887\">",
"      - Olanzapine plus fluoxetine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5519998\">",
"      Other second-generation antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36032278\">",
"      Drugs with little to no benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36032292\">",
"      Rapid cycling bipolar disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2229622\">",
"      Geriatric bipolar disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36032356\">",
"      SAFETY AND TOLERABILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H259519902\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H259517724\">",
"      - Metabolic effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H259518705\">",
"      - Sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173197509\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36032399\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/16693\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/16693|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?43/13/44243\" title=\"form 1\">",
"      Abnormal involuntary movement scale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/16693|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/53/3932\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for mania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/39/23164\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for hypomania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17756\" title=\"table 3\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/57/33694\" title=\"table 4\">",
"      Adverse effects for antipsychotic meds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/2/22571\" title=\"table 5\">",
"      Adverse effects of atypical antipsychotic medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/43/25278\" title=\"table 6\">",
"      Pharmacology antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/46/38639\" title=\"table 7\">",
"      Side effects antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/17/25884\" title=\"table 8\">",
"      Monitoring for metabolic side effects of antipsychotic drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44088?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37417?source=related_link\">",
"      Bipolar disorder in adults: Treating major depression with antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=related_link\">",
"      Causes of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16330?source=related_link\">",
"      Geriatric bipolar disorder: Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42216?source=related_link\">",
"      Rapid cycling bipolar disorder in adults: Treatment of major depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/40/27269?source=related_link\">",
"      Tardive dyskinesia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34952?source=related_link\">",
"      Tardive dyskinesia: Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_52_8010="Staphylococcal toxic shock syndrome";
var content_f7_52_8010=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Staphylococcal toxic shock syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/52/8010/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/52/8010/contributors\">",
"     Vivian H Chu, MD, MHS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/52/8010/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/52/8010/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/52/8010/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/52/8010/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/52/8010/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/52/8010/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aerobic gram-positive coccus, Staphylococcus aureus, is a ubiquitous and virulent pathogen. The organism causes a wide range of infections from folliculitis and skin abscesses to bacteremia and endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=see_link\">",
"     \"Impetigo\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22387?source=see_link\">",
"     \"Folliculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43831?source=see_link\">",
"     \"Skin abscesses, furuncles, and carbuncles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10263?source=see_link\">",
"     \"Epidemiology of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28632?source=see_link\">",
"     \"Epidemiology of and risk factors for Staphylococcus aureus bacteremia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    S. aureus also colonizes the skin and mucous membranes of 30 to 50 percent of healthy adults and children, most commonly in the anterior nares, skin, vagina, and rectum [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The organism is capable of multiplying in tissues and producing several enzymes that induce inflammation and abscesses. Many strains produce exotoxins that lead to three other syndromes: food poisoning, caused by ingestion of S. aureus enterotoxin; scalded skin syndrome, caused by exfoliative toxin; and toxic shock syndrome (TSS), caused by toxic shock syndrome toxin-1 (TSST-1) and other enterotoxins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=see_link\">",
"     \"Differential diagnosis of microbial foodborne disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term toxic shock syndrome was coined in 1978 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/2\">",
"     2",
"    </a>",
"    ], but the disease came to public attention in 1980 based upon a series of menstrual-associated cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/3\">",
"     3",
"    </a>",
"    ]. The Centers for Disease Control and Prevention (CDC) proposed a revised clinical case definition in 1981, which remains in use (",
"    <a class=\"graphic graphic_table graphicRef54778 \" href=\"UTD.htm?35/1/35868\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The incidence of disease has declined dramatically since the early epidemic of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the majority of clinically reported cases of TSS have been due to methicillin-susceptible S. aureus (MSSA) cases of TSS due to methicillin-resistant S. aureus (MRSA) have emerged, as rates of infection due to MRSA increase, particularly those due to the more virulent community-associated strains [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of staphylococcal TSS will be reviewed here. The closely related entity, streptococcal toxic shock syndrome, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8519?source=see_link\">",
"     \"Treatment of streptococcal toxic shock syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;TSS associated with S. aureus was first described in a series of pediatric cases in 1978 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence of TSS rose sharply in 1980 when there were 812 documented cases of menses-related TSS. These cases occurred most commonly in young Caucasian women; 36 percent of cases occurred in individuals 15 to 19 years of age, and 97 percent of patients were Caucasian [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/10\">",
"     10",
"    </a>",
"    ]. Clinical illness arose during menstrual periods and was associated with the use of highly absorbent tampons [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/4,11\">",
"     4,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the incidence of TSS sharply declined after the withdrawal of some brands of tampons (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Menstrual cases'",
"    </a>",
"    below), a slight increase in incidence of all TSS cases has occurred between 2000 and 2003. In one report from Minnesota, the incidence rose from 0.8 per 100,000 in 2000 to 3.4 per 100,000 in 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/12\">",
"     12",
"    </a>",
"    ]. These estimates were in women of menstrual age but included both menstrual and non-menstrual cases and may represent increased recognition in a state with an active laboratory testing for toxin-producing strains rather than an overall increase in incidence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Menstrual cases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 1979 and 1996, 5296 TSS cases were reported; underreporting is probable, especially in nonmenstrual cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/7\">",
"     7",
"    </a>",
"    ]. Cases associated with menstruation accounted for 74 percent of the total cases although the proportion decreased significantly over time (91 percent from 1979 to 1980, 71 percent from 1981 to 1986, and 59 percent from 1987 to 1996). The number of cases of menstrual TSS has declined from 9 out of 100,000 women in 1980 to 1 out of 100,000 women since 1986 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/13\">",
"     13",
"    </a>",
"    ]. The case-fatality rate has also declined for menstrual TSS from 5.5 percent in 1979 to 1980 to 2.8 and 1.8 percent in 1981 to 1986 and 1987 to 1996, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The withdrawal of highly absorbent tampons and polyacrylate rayon-containing products from the market partially explains the decrease in menstrual cases; however, tampon use remains a risk factor for TSS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/14\">",
"     14",
"    </a>",
"    ]. Women who develop TSS are more likely to have used tampons with higher absorbencies, used tampons continuously for more days of their cycle, and kept a single tampon in place for a longer period of time [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonmenstrual",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-half of reported TSS cases are nonmenstrual [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. Nonmenstrual TSS has been seen in a variety of clinical situations, including surgical and postpartum wound infections, mastitis, septorhinoplasty, sinusitis, osteomyelitis, arthritis, burns, cutaneous and subcutaneous lesions (especially of the extremities, perianal area, and axillae), respiratory infections following influenza, and enterocolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/17-25\">",
"     17-25",
"    </a>",
"    ]. The proportion of cases following surgical procedures increased from 14 percent in 1979 through 1986 to 27 percent in 1987 through 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among all cases of TSS, 93 percent involved women, and 73 percent of nonmenstrual cases were in women [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/7\">",
"     7",
"    </a>",
"    ]. However, in one study of 130 cases the distribution of cases between men and women was equal if vaginal and postpartum-associated cases were excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients with nonmenstrual TSS are significantly older (mean age 26.8 versus 23 years in patients with menstrual TSS) and more often non-white when compared to patients with menstrual TSS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/16,22,26\">",
"     16,22,26",
"    </a>",
"    ]. The case-fatality rate for nonmenstrual TSS was 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast to the menstrual cases, this rate did not decrease over time.",
"   </p>",
"   <p>",
"    TSS also occurs in children; 50 cases in children less than five years old were reported in the period between 1979 and 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients under the age of two years accounted for approximately half of these cases, and 62 percent had preceding cutaneous nonsurgical lesions. Cutaneous nonsurgical lesions were far more common among children than other patients with nonmenstrual TSS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Methicillin-resistant S. aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRSA strains can produce TSST-1 and patients infected with these strains may develop TSS. In a series of 30 patients with TSST-1-positive MRSA infections from France and Switzerland, five had TSS, nine had possible TSS (fever and a rash without shock), two had neonatal toxic shock syndrome-like exanthematous disease (NTED), one had scarlet fever, and the remaining had other infections [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/8\">",
"     8",
"    </a>",
"    ]. Nine of 30 (30 percent) cases were community-acquired and the rest were hospital-acquired or had an unknown site of acquisition. NTED has also been reported in neonates in Japan and France who are colonized with TSST-1-producing MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A laboratory study compared toxin production in 32 community-associated MRSA strains, 32 hospital-acquired MRSA strains, and 21 S. aureus isolates from patients with nonmenstrual toxic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/9\">",
"     9",
"    </a>",
"    ]. Thirty-one of the 32 community-associated MRSA strains were highly related based on molecular typing and produced either enterotoxin B (15 percent) or enterotoxin C (81 percent), but not TSST-1. The hospital-acquired strains were not related to the community-acquired strains and did not produce enterotoxin B or C or TSST-1. Six of 21 (29 percent) nonmenstrual toxic shock strains were identical or highly related to the community-acquired strains, 16 produced either enterotoxin B or C, and none produced TSST-1. This study suggests that community-acquired MRSA strains may be more likely to cause TSS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of shock, erythroderma, and multiorgan system involvement implicated toxin(s) as a pathogenic mechanism in early investigations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Toxic shock syndrome toxin-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;TSST-1 was the initial exotoxin isolated from S. aureus isolates implicated in TSS in 1981 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. It is produced by 90 to 100 percent of S. aureus strains associated with menstrual cases of TSS and by 40 to 60 percent of strains associated with nonmenstrual cases. In studies to examine the neurologic manifestations caused by TSST-1 during TSS, TSST-1 increased intracerebral prostaglandin E2 and caused caspase-dependent neuronal death in a neural cell line and, in vitro, in primary cortical neuron cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reasons that more strains causing menstrual TSS produce TSST-1 is not known. Hypotheses include structural differences that allow TSST-1 to transverse the vaginal mucosa or phenotypic differences in TSST-1 containing S. aureus strains that facilitate vaginal colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that nonmenstrual strains were less likely to produce TSST-1 led investigators to postulate the existence of other causative toxins. Staphylococcal enterotoxin B is produced by between 38 and 62 percent of nonmenstrual, TSST-1 negative strains potentially implicating this toxin in TSS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Several animal studies suggest that enterotoxin A may be a cofactor along with TSST-1 in TSS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. A mutant strain deficient in enterotoxin A but producing TSST-1 was significantly less lethal in a mouse model compared to a S. aureus strain, which produced both toxins (70 versus 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/35\">",
"     35",
"    </a>",
"    ]. However, TSST-1 appeared to be the principal agent of menstrual TSS in a rabbit tampon model in which strains mutant in TSST-1 but not enterotoxin A production were less virulent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other enterotoxins, specifically enterotoxins C, D, E, and H have been implicated in a smaller number of cases. In a study of 183 isolates of S. aureus from clinical specimens but not necessarily cases of TSS, 40 percent of the strains produced one or more toxins [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/37\">",
"     37",
"    </a>",
"    ]. Fourteen percent of isolates produced TSST-1, and 20, 8, 6, and 3 percent, enterotoxins A, B, C, and D, respectively. Blood culture isolates were more likely to produce enterotoxin D. The significance of these observations is not yet understood.",
"   </p>",
"   <p>",
"    Some investigators have postulated that other toxins may be more virulent than TSST-1; in one study of 32 S. aureus isolates from nonmenstrual TSS, five of 10 persons (50 percent) infected with a TSST-1 negative strain died, compared to only two of 20 (10 percent) with TSST-1 positive strains [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Superantigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. aureus exotoxins cause disease because they are superantigens. Superantigens are molecules that are able to activate large numbers of T cells, often up to 20 percent of all T cells at one time, resulting in massive cytokine production [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/39\">",
"     39",
"    </a>",
"    ]. In typical T cell recognition, an antigen is taken up by an antigen-presenting cell, processed, expressed on the cell surface in complex with class II major histocompatibility complex (MHC) in a groove formed by the alpha and beta chains of class II MHC, and recognized by an antigen-specific T cell receptor. By contrast, superantigens do not require processing by antigen-presenting cells but instead interact directly with the invariant region of the class II MHC molecule. Two regions of the TSST-1 toxin within the beta",
"    <span class=\"nowrap\">",
"     1/beta",
"    </span>",
"    2 and beta",
"    <span class=\"nowrap\">",
"     3/beta",
"    </span>",
"    4 loops have been found to be important for MHC class II binding [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/40\">",
"     40",
"    </a>",
"    ]. The superantigen-MHC complex then interacts with the T cell receptor at the variable (V) part of the beta chain. Thus, all T cells with a recognized V beta region are stimulated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Activated T cells then release interleukin (IL)-1, IL-2, tumor necrosis factor (TNF)-alpha and TNF-beta, and interferon (IFN)-gamma in large amounts, resulting in the signs and symptoms of TSS. IL-1 is an endogenous pyrogen and thus causes the high fevers associated with TSS. In addition, IL-1 mediates skeletal muscle proteolysis and probably accounts for the myalgia and elevated creatine phosphokinase (CPK) seen in TSS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/10/8361?source=see_link\">",
"     \"Pathophysiology and treatment of fever in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=see_link&amp;anchor=H48346159#H48346159\">",
"     \"Pathophysiology and management of fever in infants and children\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The production of TNF inhibits both random and chemotactic migratory polymorphonuclear leukocyte (PMN) functions. TSST-1-producing S. aureus do not engender a purulent response, which in part may be explained by PMN inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, data suggest that TSST-1 and enterotoxin B repress the production of other S. aureus exoproteins, which may explain the absence of purulence in S. aureus infections associated with TSS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/43\">",
"     43",
"    </a>",
"    ]. It has also been postulated that endogenous endotoxin, most likely from the gastrointestinal tract, enhances susceptibility to TSST-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antibody responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Host antibody responses to the S. aureus exotoxins play an important role in the pathogenesis of TSS. Approximately 70 to 80 percent of individuals develop antibody to TSST-1 by the late teenage years, and by the fourth decade 90 to 95 percent have such antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. One study found that 76 percent of infants from birth to six months of age had positive antibody titers to TSST-1, compared to only 30 to 33 percent of infants between the ages of seven months and two years. Thus the age of six months to two years corresponds to a period of vulnerability as passive immunity conferred by the mother at birth is waning and acquired antibodies have not been obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with clinical TSS lack antibody to TSST-1 and often fail to develop appropriate antibodies in convalescent serum [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/48\">",
"     48",
"    </a>",
"    ]. Decreased titers to the other staphylococcal enterotoxins in patients with TSS have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/29\">",
"     29",
"    </a>",
"    ]. Individuals with TSS may fail to have an appropriate antibody response because superantigen-mediated production of IFN-gamma inhibits polyclonal immunoglobulin production [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/49\">",
"     49",
"    </a>",
"    ]. This failure to develop antibodies may explain why some patients are predisposed to relapse after a first episode of TSS.",
"   </p>",
"   <p>",
"    It is likely that varying factors are responsible for how superantigen-mediated disease affects different hosts. Genetically determined tendencies to produce different amounts of cytokines as well as titer of circulating antitoxin antibodies and the particular V beta segment that is recognized all probably play a role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of TSS are diverse based upon the action of the S. aureus toxin(s). As noted above, the CDC established a case definition in 1981, which continues to serve as the criterion for this reportable illness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/4\">",
"     4",
"    </a>",
"    ]. The symptoms and signs of TSS develop rapidly, usually in otherwise healthy individuals. Reports suggest that the median interval between the onset of menstruation and TSS is two to three days in menstrual cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/50\">",
"     50",
"    </a>",
"    ] and the onset of symptoms in post-surgical cases is two days, although the onset has been reported as late as 65 days post-operatively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/17,26\">",
"     17,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with TSS commonly have fever, hypotension, and skin manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Additional symptoms and signs include: chills, malaise, headache, sore throat, myalgias, fatigue, vomiting, diarrhea, abdominal pain, and orthostatic dizziness or syncope. The CDC case definition criteria established for epidemiologic surveillance should be not be used to exclude a case that is highly suspicious for TSS, even if all criteria are not met (",
"    <a class=\"graphic graphic_table graphicRef54778 \" href=\"UTD.htm?35/1/35868\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    During the initial 48 hours of hospitalization patients may develop diffuse erythroderma, severe watery diarrhea, decreased urine output, cyanosis, and edema of the extremities. Neurologic symptoms such as somnolence, confusion, irritability, agitation, and hallucinations may occur secondary to cerebral ischemia and edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rapid onset of hypotension, defined as either a systolic blood pressure of &le;90 mmHg for adults or less than fifth percentile by age for children &lt;16 years of age, or an orthostatic decline in diastolic blood pressure of &ge;15 mmHg, or orthostatic syncope or dizziness, often leads to subsequent tissue ischemia and organ failure. The hypotension is caused by a decrease in systemic vascular resistance as well as nonhydrostatic leakage of fluid from the intravascular space to the interstitial space [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/51\">",
"     51",
"    </a>",
"    ], both of which occur as a consequence of the massive cytokine release induced by the responsible toxins. The hypotension can be unresponsive to large amounts of intravenous fluids and can persist for several days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Skin manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of skin manifestations are seen in TSS. The initial erythroderma involves both the skin and the mucous membranes and is characterized by a diffuse, red, macular rash resembling sunburn that also involves the palms and soles (",
"    <a class=\"graphic graphic_picture graphicRef77600 \" href=\"UTD.htm?30/23/31103\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef82561 \" href=\"UTD.htm?29/4/29761\">",
"     picture 2",
"    </a>",
"    ). This rash can be subtle and fleeting. In postoperative TSS, the erythema may be more intense around the involved surgical wound site. Mucosal involvement includes conjunctival-scleral hemorrhage and hyperemia of the vaginal and oropharyngeal mucosa (",
"    <a class=\"graphic graphic_picture graphicRef66457 \" href=\"UTD.htm?36/46/37615\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/52\">",
"     52",
"    </a>",
"    ]. In more severe cases, superficial ulcerations occur on the mucous membranes, and petechiae, vesicles, and bullae develop. Patients will also have nonpitting edema as a consequence of increases in interstitial fluid.",
"   </p>",
"   <p>",
"    Late-onset skin manifestations include a pruritic maculopapular rash that may occur one to two weeks after the disease onset and desquamation of the palms and soles that characteristically begins one to three weeks after illness develops (",
"    <a class=\"graphic graphic_picture graphicRef59735 \" href=\"UTD.htm?37/25/38290\">",
"     picture 4",
"    </a>",
"    ). Since desquamation occurs late, the acute diagnosis of TSS cannot take advantage of this clinical feature. In fact, TSS may not even be considered in the differential diagnosis in some cases until later when desquamation is observed; this is particularly true in nonmenstrual disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/53\">",
"     53",
"    </a>",
"    ]. Some patients also experience loss of hair and nails one to two months later with regrowth by six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Multiorgan system involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;TSS can involve all organ systems. Many patients report diffuse myalgias and weakness as presenting symptoms, which are usually accompanied by an increase in serum concentrations of creatine phosphokinase (CPK). Gastrointestinal symptoms are also common, particularly profuse diarrhea. Both prerenal and intrinsic renal failure can occur and are often accompanied by other metabolic abnormalities including hyponatremia, hypoalbuminemia, hypocalcemia, and hypophosphatemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Encephalopathy, manifested by disorientation, confusion, or seizure activity, can be a presenting symptom of TSS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/55\">",
"     55",
"    </a>",
"    ] and is probably due to cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/56\">",
"     56",
"    </a>",
"    ]. Other central nervous system (CNS) findings have been reported in some patients. Persistent neuropsychological sequelae can develop such as headaches, memory loss, and poor concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/57\">",
"     57",
"    </a>",
"    ]. Other findings include pulmonary edema and pleural effusions, depression of myocardial function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/58\">",
"     58",
"    </a>",
"    ], hepatic dysfunction, and hematologic abnormalities, such as anemia and thrombocytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Menstrual versus nonmenstrual cases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentations of menstrual and nonmenstrual TSS are similar. In one small study, nonmenstrual TSS was associated with earlier onset of rash and fever, more pronounced renal and CNS complications, and less musculoskeletal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/59\">",
"     59",
"    </a>",
"    ]. Surgical wound sites and cutaneous infections that harbor toxin-producing S. aureus are frequently benign-appearing without obvious purulence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/26,59\">",
"     26,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Recurrent illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episodes of recurrent TSS have been reported. Recurrent TSS tends to occur in patients who have not been treated with appropriate courses of anti-staphylococcal antimicrobials and who fail to develop an appropriate antibody response to staphylococcal toxins [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/22,53,60\">",
"     22,53,60",
"    </a>",
"    ]. In menstrual TSS, recurrent episodes are generally milder than the initial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrence can occur days to months after the initial episode. There is also a variant of TSS described in patients with the acquired immunodeficiency syndrome (AIDS). This presentation is characterized by a subacute illness with persistent and recalcitrant erythroderma, desquamation, mucosal injection, fever, and hypotension lasting or recurring over a period of weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in clinical laboratory tests will reflect shock and organ failure. Leukocytosis may not be present, but the total number of mature and immature neutrophils usually exceeds 90 percent, with immature neutrophils accounting for 25 to 50 percent of the total number of neutrophils. Thrombocytopenia and anemia are present during the first few days, frequently accompanied by prolonged prothrombin and partial thromboplastin times. Disseminated intravascular coagulation may be present.",
"   </p>",
"   <p>",
"    Other laboratory abnormalities reflect multiorgan failure with elevated blood urea nitrogen and creatinine, elevated liver function tests, and an elevated creatine phosphokinase [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/54,62,63\">",
"     54,62,63",
"    </a>",
"    ]. Most laboratory tests will return to normal within seven to 10 days after disease onset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the diagnosis of TSS is based upon clinical presentation, utilizing the CDC case definition (",
"    <a class=\"graphic graphic_table graphicRef54778 \" href=\"UTD.htm?35/1/35868\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/6,64\">",
"     6,64",
"    </a>",
"    ]. To meet the CDC case definition for a confirmed case, patients must have fever &gt;38.9&ordm;C, hypotension, diffuse erythroderma, desquamation (unless the patient dies before desquamation can occur), and involvement of at least three organ systems. A probable case is a patient who is missing one of the characteristics of the confirmed case definition. However, these criteria were established for epidemiologic surveillance and should be not be used to exclude a case that is highly suspicious for TSS, even if all criteria are not met.",
"   </p>",
"   <p>",
"    Although 80 to 90 percent of TSS patients have S. aureus isolated from mucosal or wound sites [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/60\">",
"     60",
"    </a>",
"    ], the isolation of S. aureus is",
"    <strong>",
"     not",
"    </strong>",
"    required for the diagnosis of staphylococcal TSS. In contrast to streptococcal TSS, S. aureus is only rarely (5 percent) recovered from blood cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cultures from mucosal and wound sites should be obtained because S. aureus isolates can be tested for toxin production in research laboratories. In addition, these laboratories can analyze acute and convalescent serum for antibody responses to various S. aureus exotoxins. The presence of a strain of S. aureus that produces toxin in a patient who does not have acute phase antibody to the toxin is highly suggestive of TSS. These tests can be helpful in making a retrospective diagnosis in cases suspicious for TSS, however, the tests are not available in clinical laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few illnesses lead to the rapid onset of shock symptoms in young, healthy people as in the case of menstrual TSS. Other diagnostic considerations would include streptococcal TSS, which is most often associated with severe pain and tenderness signifying infection at a site of local trauma in addition to the other manifestations of TSS. It is important to distinguish between these two entities because patients with streptococcal TSS may require immediate surgical debridement of the involved site. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8519?source=see_link\">",
"     \"Treatment of streptococcal toxic shock syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other diagnostic possibilities include Rocky Mountain spotted fever (RMSF), although the rash associated with RMSF typically is petechial, involves the extremities first, and occurs an average of three days after the development of fever. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Rocky Mountain spotted fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Meningococcemia is another important diagnostic consideration for shock in a young person; again, the petechiae and purpura found in this disease are different from the skin findings in S. aureus TSS. In addition, meningitis is frequently seen in conjunction with meningococcemia and is rare in TSS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=see_link\">",
"     \"Clinical manifestations of meningococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other more unusual illnesses can be considered if there is an appropriate exposure such as leptospirosis, dengue hemorrhagic fever, and typhoid fever. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43879?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18985?source=see_link\">",
"     \"Clinical presentation and diagnosis of dengue virus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=see_link\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the aforementioned illnesses, the differential diagnosis for patients with suspected nonmenstrual TSS should include nosocomially-acquired sepsis from gram-negative or gram-positive pathogens. These organisms should be recovered in blood cultures to make a diagnosis; the type of bacterium isolated may provide a clue about the origin of the infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of treatment for TSS is supportive while hypotension is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Supportive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may require extensive fluid replacement (10 to 20 liters per day) to maintain perfusion because of intractable hypotension and diffuse capillary leak. Although the blood pressure may improve with fluids alone, vasopressors (eg, dopamine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    norepinephrine) may also be required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Episodes of menstrual TSS can resolve with supportive care only, although recurrences were noted in the early case series when antistaphylococcal antibiotics were not administered [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An examination for the presence of foreign material in the vaginal canal (eg, tampons, contraceptive sponges) should be undertaken, and these materials should be removed. Drainage of any identified infectious focus is essential. In post-surgical patients, surgical wounds may not appear to be infected because of the decreased inflammatory response but should nevertheless be explored and debrided if the patient fulfills the clinical criteria for TSS.",
"   </p>",
"   <p>",
"    Culture of the vaginal canal in cases of menstrual TSS and of material obtained from an infectious focus or surgical wound in nonmenstrual cases should be submitted for culture and susceptibility testing, as TSS is caused by both MSSA and MRSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not clear whether antibiotics alter the course of acute TSS, however antistaphylococcal antibiotic therapy is needed to eradicate organisms and to prevent recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/3,60\">",
"     3,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Theoretically, antibiotics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    that suppress protein synthesis and, therefore, toxin synthesis may be more efficacious than cell wall active agents such as beta-lactams. This finding has been demonstrated in vitro; subinhibitory concentrations of clindamycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , and fluoroquinolones suppressed TSST-1 synthesis by 90 percent, while five different beta-lactam antibiotics, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    and cephalosporins, increased measurable TSST-1 in culture supernatants, probably by lysis or increasing cell membrane permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case report of successful treatment of TSS with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    and in vitro analysis of TSST-1 synthesis of the S. aureus isolate supports the superior efficacy of protein synthesis inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    and linezolid) to cell wall active agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and beta-lactam antibiotics) in TSS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/66\">",
"     66",
"    </a>",
"    ]. The patient's S. aureus isolate was cultured in medium to optimize TSST-1 production in the presence or absence of antibiotics. Maximal TSST-1 production occurred in the untreated,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    -treated, and vancomycin-treated cultures. In contrast, linezolid and clindamycin completely suppressed toxin synthesis.",
"   </p>",
"   <p>",
"    No randomized controlled studies have evaluated antibiotic regimens for treatment of TSS, thus recommendations are based upon animal studies and clinical case series. We recommend that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients with suspected TSS receive empiric treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (adults: 600 mg IV every eight hours; children: 25 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three divided doses)",
"      <strong>",
"       plus",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (adults: 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in two divided doses; children: 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in four divided doses).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend that if culture and sensitivity results are available that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with TSS due to methicillin-susceptible S. aureus receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (if susceptible) (adults: 600 mg IV every eight hours; children: 25 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three divided doses)",
"      <strong>",
"       plus",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"       oxacillin",
"      </a>",
"      &nbsp;",
"      <strong>",
"       or",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"       nafcillin",
"      </a>",
"      (2 g IV every four hours; children: 100 to 150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per 24 h IV in 4 divided doses).",
"     </li>",
"     <li>",
"      Patients with TSS due to MRSA receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (if susceptible) (adults: 600 mg IV every eight hours; children: 25 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three divided doses)",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (adults: 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in two divided doses; children: 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in four divided doses)",
"      <strong>",
"       or",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      alone (adults: 600 mg oral or IV every 12 hours; children: 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      oral or IV every 12 hours) or in combination with vancomycin (adults: 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in two divided doses; children: 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in four divided doses), depending on the source of infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    may be adequate single drug therapy for a drained infected focus such as a surgical wound, we recommend combination therapy of clindamycin and an antistaphylococcal penicillin (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    for patients with deep-seated infections (eg, osteomyelitis) or bacteremia, at least until the patient stabilizes.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    can be considered as a second agent for deep-seated infections in the event of resistance to clindamycin. Antibiotic therapy clearly reduces the likelihood of recurrent TSS by eliminating the carrier state [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We typically treat with a one to two week course of an anti-staphylococcal agent even in the absence of overt S. aureus infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Eradication of carrier state",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with S. aureus TSS, an attempt should be made to eradicate nasal carriage, if present; thus, nares cultures should be sent and the patient treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    if positive. However, there are",
"    <strong>",
"     no",
"    </strong>",
"    data to support this practice. In a study examining the effect of topical antimicrobials on TSST-1 production, silver sulphadiazine, which is used routinely for burns, caused a fourfold increase in toxin production in 45 percent of strains. By contrast, mupirocin ointment decreased toxin production in 47 percent of strains and caused no increased toxin from any strains [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    involves applying one-half of the ointment from a single-use tube into one nostril and the other half into the other nostril twice daily for five days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Additional therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in rabbit models of TSS have demonstrated that administration of antibody to TSST-1 is protective [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no controlled trials of intravenous immune globulin (IVIG) therapy in staphylococcal TSS in humans, although if an individual is susceptible to TSS because of diminished antibody production to toxin, it is a logical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Treatment with IVIG may be efficacious in streptococcal toxic shock, another superantigen-mediated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. A report from Sweden noted that culture supernatants containing superantigen from S. aureus were less efficiently inhibited by IVIG than those from S. pyogenes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8519?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of streptococcal toxic shock syndrome\", section on 'Intravenous immune globulin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A single case report of the use of IVIG in staphylococcal TSS describes a 39 year-old HIV-infected man with diffuse erythema of the arms and legs, desquamation of the arms, hands, feet, and eyebrows, pharyngeal erythema, and a toe lesion that grew a TSST-1 producing S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/61\">",
"     61",
"    </a>",
"    ]. He received IVIG (200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for five days after failing antibiotic therapy and had resolution of his symptoms.",
"   </p>",
"   <p>",
"    A controlled trial to evaluate the efficacy of IVIG in TSS is unlikely. However, it seems reasonable to use IVIG (400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in a single dose administered over several hours) in severe cases of TSS that are recognized early in their course but have not responded to fluids and vasopressors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/70\">",
"     70",
"    </a>",
"    ]. Based upon the Swedish report, higher doses may be necessary in TSS due to S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some investigators have advocated the use of high dose corticosteroids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    10 to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for TSS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/75\">",
"     75",
"    </a>",
"    ]. In a retrospective study in which 25 patients who received steroids were compared to 20 patients who did not, patients treated within two to three days of the onset of TSS had reduced severity of illness and duration of fever, although there was no difference in mortality. We do not recommend corticosteroid treatment in TSS because of the limited clinical data with this therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Death associated with TSS usually occurs within the first few days of hospitalization but may occur as late as 15 days after admission. Fatalities have been attributed to refractory cardiac arrhythmias, cardiomyopathy, irreversible respiratory failure, and rarely bleeding caused by coagulation defects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The TSS-related mortality rate in menstrual cases has decreased since the syndrome was first recognized in 1980, from 5.5 to 1.8 percent in 1987 to 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/7\">",
"     7",
"    </a>",
"    ]. The mortality due to nonmenstrual TSS is higher and has remained essentially unchanged from 1980 to 1996 at approximately 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/7,14\">",
"     7,14",
"    </a>",
"    ]. The mortality due to TSS in children is 3 to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/52/8010/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who have had tampon-associated TSS should not resume using tampons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Staphylococcus aureus strains produce exotoxins that lead to three syndromes: food poisoning, caused by ingestion of S. aureus enterotoxin; scalded skin syndrome, caused by exfoliative toxin; and toxic shock syndrome (TSS), caused by toxic shock syndrome toxin-1 (TSST-1) and other enterotoxins. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately one-half of reported TSS cases are menstrual, associated with highly absorbent tampons, and one-half is nonmenstrual. Nonmenstrual TSS has been associated with surgical and postpartum wound infections, mastitis, septorhinoplasty, sinusitis, osteomyelitis, arthritis, burns, cutaneous and subcutaneous lesions (especially of the extremities, perianal area, and axillae), and respiratory infections following influenza. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Methicillin-resistant S. aureus (MRSA) strains can produce TSST-1 and patients infected with these strains may develop TSS. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Methicillin-resistant S. aureus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Host antibody responses to the S. aureus exotoxins play an important role in the pathogenesis of TSS. Seventy to 80 percent of individuals develop antibody to TSST-1 by the late teenage years, and by the fourth decade 90 to 95 percent have such antibody. Patients with clinical TSS lack antibody to TSST-1 and often fail to develop appropriate antibodies in convalescent serum. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Antibody responses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms and signs of TSS develop rapidly, usually in otherwise healthy individuals. Patients with TSS commonly have fever, hypotension, and skin manifestations. In addition, TSS can involve all organ systems (",
"      <a class=\"graphic graphic_table graphicRef54778 \" href=\"UTD.htm?35/1/35868\">",
"       table 1",
"      </a>",
"      ). The CDC case definition criteria established for epidemiologic surveillance should be not be used to exclude a case that is highly suspicious for TSS, even if all criteria are not met. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The CDC case definition for a confirmed case includes the following: patients must have fever &gt;38.9&ordm;C, hypotension, diffuse erythroderma, desquamation (unless the patient dies before desquamation can occur), and involvement of at least three organ systems. A probable case is a patient who is missing one of the characteristics of the confirmed case definition. Although 80 to 90 percent of TSS patients have S. aureus isolated from mucosal or wound sites, the isolation of S. aureus is",
"      <strong>",
"       not",
"      </strong>",
"      required for the diagnosis of staphylococcal TSS. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mainstay of treatment for TSS is supportive while hypotension is present. An examination for the presence of foreign material in the vaginal canal (eg, tampons, contraceptive sponges) should be undertaken, and these materials should be removed. Drainage of any identified infectious focus is essential. Exploration of surgical wounds in postoperative TSS is imperative. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is not clear whether antibiotics alter the course of acute TSS. No randomized controlled studies have evaluated antibiotic regimens for treatment of TSS, thus recommendations are based upon animal studies and clinical case series. We recommend that all patients with suspected TSS receive combination antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ), at least until the patient stabilizes. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We typically use the following regimens:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Empiric treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (adults: 600 mg IV every eight hours; children: 25 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three divided doses) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (adults: 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in two divided doses; children: 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in four divided doses).",
"     </li>",
"     <li>",
"      In patients with TSS due to methicillin-susceptible S. aureus, we use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (if susceptible) (adults: 600 mg IV every eight hours; children: 25 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three divided doses)",
"      <strong>",
"       plus",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"       oxacillin",
"      </a>",
"      &nbsp;",
"      <strong>",
"       or",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"       nafcillin",
"      </a>",
"      (2 g IV every four hours; children: 100 to 150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per 24 h IV in 4 divided doses).",
"     </li>",
"     <li>",
"      In patients with TSS due to MRSA, we use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (if susceptible) (adults: 600 mg IV every eight hours; children: 25 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three divided doses)",
"      <strong>",
"       plus",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (adults: 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in two divided doses; children: 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in four divided doses)",
"      <strong>",
"       or",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      alone (adults: 600 mg oral or IV every 12 hours; children: 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      oral or IV every 12 hours) or in combination with vancomycin (adults: 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in two divided doses; children: 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in four divided doses), depending on the source of infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Antibiotic therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We typically treat with a one to two week course of an anti-staphylococcal agent even in the absence of overt S. aureus infection. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest screening for S. aureus nasal carriage in patients with S. aureus TSS followed by treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"       mupirocin",
"      </a>",
"      in those with positive nares cultures. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Eradication of carrier state'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment with intravenous immune globulin (typically, 400",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in a single dose administered over several hours) in severe cases of TSS in patients that are recognized early in their course who have not responded to fluids and vasopressors. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Intravenous immune globulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <strong>",
"       NOT",
"      </strong>",
"      treating with corticosteroids in TSS. (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7913091\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate Inc. would like to acknowledge Dr. Sara Cosgrove, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/1\">",
"      Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997; 10:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/2\">",
"      Todd J, Fishaut M, Kapral F, Welch T. Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet 1978; 2:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/3\">",
"      Davis JP, Chesney PJ, Wand PJ, LaVenture M. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med 1980; 303:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/4\">",
"      Reingold AL, Hargrett NT, Shands KN, et al. Toxic shock syndrome surveillance in the United States, 1980 to 1981. Ann Intern Med 1982; 96:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/5\">",
"      Wharton M, Chorba TL, Vogt RL, et al. Case definitions for public health surveillance. MMWR Recomm Rep 1990; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/6\">",
"      Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention. MMWR Recomm Rep 1997; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/7\">",
"      Hajjeh RA, Reingold A, Weil A, et al. Toxic shock syndrome in the United States: surveillance update, 1979 1996. Emerg Infect Dis 1999; 5:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/8\">",
"      Durand G, Bes M, Meugnier H, et al. Detection of new methicillin-resistant Staphylococcus aureus clones containing the toxic shock syndrome toxin 1 gene responsible for hospital- and community-acquired infections in France. J Clin Microbiol 2006; 44:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/9\">",
"      Fey PD, Sa&iuml;d-Salim B, Rupp ME, et al. Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/10\">",
"      Centers for Disease Control (CDC). Update: toxic-shock syndrome--United States. MMWR Morb Mortal Wkly Rep 1983; 32:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/11\">",
"      Osterholm MT, Davis JP, Gibson RW, et al. Toxic shock syndrome: relation to catamenial products, personal health and hygiene, and sexual practices. Ann Intern Med 1982; 96:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/12\">",
"      Schlievert PM, Tripp TJ, Peterson ML. Reemergence of staphylococcal toxic shock syndrome in Minneapolis-St. Paul, Minnesota, during the 2000-2003 surveillance period. J Clin Microbiol 2004; 42:2875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/13\">",
"      Centers for Disease Control (CDC). Reduced incidence of menstrual toxic-shock syndrome--United States, 1980-1990. MMWR Morb Mortal Wkly Rep 1990; 39:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/14\">",
"      Broome CV. Epidemiology of toxic shock syndrome in the United States: overview. Rev Infect Dis 1989; 11 Suppl 1:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/15\">",
"      Reingold AL, Broome CV, Gaventa S, Hightower AW. Risk factors for menstrual toxic shock syndrome: results of a multistate case-control study. Rev Infect Dis 1989; 11 Suppl 1:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/16\">",
"      Gaventa S, Reingold AL, Hightower AW, et al. Active surveillance for toxic shock syndrome in the United States, 1986. Rev Infect Dis 1989; 11 Suppl 1:S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/17\">",
"      Bartlett P, Reingold AL, Graham DR, et al. Toxic shock syndrome associated with surgical wound infections. JAMA 1982; 247:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/18\">",
"      Dann EJ, Weinberger M, Gillis S, et al. Bacterial laryngotracheitis associated with toxic shock syndrome in an adult. Clin Infect Dis 1994; 18:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/19\">",
"      Ferguson MA, Todd JK. Toxic shock syndrome associated with Staphylococcus aureus sinusitis in children. J Infect Dis 1990; 161:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/20\">",
"      Morrison VA, Oldfield EC 3rd. Postoperative toxic shock syndrome. Arch Surg 1983; 118:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/21\">",
"      Paterson MP, Hoffman EB, Roux P. Severe disseminated staphylococcal disease associated with osteitis and septic arthritis. J Bone Joint Surg Br 1990; 72:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/22\">",
"      Reingold AL, Hargrett NT, Dan BB, et al. Nonmenstrual toxic shock syndrome: a review of 130 cases. Ann Intern Med 1982; 96:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/23\">",
"      Vuzevski VD, van Joost T, Wagenvoort JH, Dey JJ. Cutaneous pathology in toxic shock syndrome. Int J Dermatol 1989; 28:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/24\">",
"      Kotler DP, Sandkovsky U, Schlievert PM, Sordillo EM. Toxic shock-like syndrome associated with staphylococcal enterocolitis in an HIV-infected man. Clin Infect Dis 2007; 44:e121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/25\">",
"      MacDonald KL, Osterholm MT, Hedberg CW, et al. Toxic shock syndrome. A newly recognized complication of influenza and influenzalike illness. JAMA 1987; 257:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/26\">",
"      Reingold AL, Dan BB, Shands KN, Broome CV. Toxic-shock syndrome not associated with menstruation. A review of 54 cases. Lancet 1982; 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/27\">",
"      Kikuchi K, Takahashi N, Piao C, et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus strains causing neonatal toxic shock syndrome-like exanthematous disease in neonatal and perinatal wards. J Clin Microbiol 2003; 41:3001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/28\">",
"      van der Mee-Marquet N, Lina G, Quentin R, et al. Staphylococcal exanthematous disease in a newborn due to a virulent methicillin-resistant Staphylococcus aureus strain containing the TSST-1 gene in Europe: an alert for neonatologists. J Clin Microbiol 2003; 41:4883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/29\">",
"      Bergdoll MS, Crass BA, Reiser RF, et al. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates. Lancet 1981; 1:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/30\">",
"      Schlievert PM, Shands KN, Dan BB, et al. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J Infect Dis 1981; 143:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/31\">",
"      Batisson M, Strazielle N, Hejmadi M, et al. Toxic shock syndrome toxin-1 challenges the neuroprotective functions of the choroidal epithelium and induces neurotoxicity. J Infect Dis 2006; 194:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/32\">",
"      Schlievert PM, Jablonski LM, Roggiani M, et al. Pyrogenic toxin superantigen site specificity in toxic shock syndrome and food poisoning in animals. Infect Immun 2000; 68:3630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/33\">",
"      Schlievert PM. Staphylococcal enterotoxin B and toxic-shock syndrome toxin-1 are significantly associated with non-menstrual TSS. Lancet 1986; 1:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/34\">",
"      Lee VT, Chang AH, Chow AW. Detection of staphylococcal enterotoxin B among toxic shock syndrome (TSS)- and non-TSS-associated Staphylococcus aureus isolates. J Infect Dis 1992; 166:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/35\">",
"      De Boer ML, Kum WW, Pang LT, Chow AW. Co-production of staphylococcal enterotoxin A with toxic shock syndrome toxin-1 (TSST-1) enhances TSST-1 mediated mortality in a D-galactosamine sensitized mouse model of lethal shock. Microb Pathog 1999; 27:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/36\">",
"      De Boer ML, Kum WW, Chow AW. Staphylococcus aureus isogenic mutant, deficient in toxic shock syndrome toxin-1 but not staphylococcal enterotoxin A production, exhibits attenuated virulence in a tampon-associated vaginal infection model of toxic shock syndrome. Can J Microbiol 1999; 45:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/37\">",
"      Lehn N, Schaller E, Wagner H, Kr&ouml;nke M. Frequency of toxic shock syndrome toxin- and enterotoxin-producing clinical isolates of Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1995; 14:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/38\">",
"      Garbe PL, Arko RJ, Reingold AL, et al. Staphylococcus aureus isolates from patients with nonmenstrual toxic shock syndrome. Evidence for additional toxins. JAMA 1985; 253:2538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/39\">",
"      Schlievert PM. Role of superantigens in human disease. J Infect Dis 1993; 167:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/40\">",
"      Kum WW, Laupland KB, Chow AW. Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality. Can J Microbiol 2000; 46:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/41\">",
"      Choi Y, Lafferty JA, Clements JR, et al. Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J Exp Med 1990; 172:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/42\">",
"      Parsonnet J. Mediators in the pathogenesis of toxic shock syndrome: overview. Rev Infect Dis 1989; 11 Suppl 1:S263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/43\">",
"      Vojtov N, Ross HF, Novick RP. Global repression of exotoxin synthesis by staphylococcal superantigens. Proc Natl Acad Sci U S A 2002; 99:10102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/44\">",
"      Stone RL, Schlievert PM. Evidence for the involvement of endotoxin in toxic shock syndrome. J Infect Dis 1987; 155:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/45\">",
"      Vergeront JM, Stolz SJ, Crass BA, et al. Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: implications for toxic-shock syndrome. J Infect Dis 1983; 148:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/46\">",
"      Parsonnet J, Hansmann MA, Delaney ML, et al. Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women. J Clin Microbiol 2005; 43:4628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/47\">",
"      Quan L, Morita R, Kawakami S. Toxic shock syndrome toxin-1 (TSST-1) antibody levels in Japanese children. Burns 2010; 36:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/48\">",
"      Bonventre PF, Linnemann C, Weckbach LS, et al. Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers. J Infect Dis 1984; 150:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/49\">",
"      Bohach GA, Fast DJ, Nelson RD, Schlievert PM. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 1990; 17:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/50\">",
"      Tofte RW, Williams DN. Toxic shock syndrome. Evidence of a broad clinical spectrum. JAMA 1981; 246:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/51\">",
"      Chesney PJ. Clinical aspects and spectrum of illness of toxic shock syndrome: overview. Rev Infect Dis 1989; 11 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/52\">",
"      Chesney PJ, Davis JP, Purdy WK, et al. Clinical manifestations of toxic shock syndrome. JAMA 1981; 246:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/53\">",
"      Andrews MM, Parent EM, Barry M, Parsonnet J. Recurrent nonmenstrual toxic shock syndrome: clinical manifestations, diagnosis, and treatment. Clin Infect Dis 2001; 32:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/54\">",
"      Chesney RW, Chesney PJ, Davis JP, Segar WE. Renal manifestations of the staphylococcal toxic-shock syndrome. Am J Med 1981; 71:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/55\">",
"      Barrett JA, Graham DR. Toxic shock syndrome presenting as encephalopathy. J Infect 1986; 12:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/56\">",
"      Smith DB, Gulinson J. Fatal cerebral edema complicating toxic shock syndrome. Neurosurgery 1988; 22:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/57\">",
"      Rosene KA, Copass MK, Kastner LS, et al. Persistent neuropsychological sequelae of toxic shock syndrome. Ann Intern Med 1982; 96:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/58\">",
"      Olson RD, Stevens DL, Melish ME. Direct effects of purified staphylococcal toxic shock syndrome toxin 1 on myocardial function of isolated rabbit atria. Rev Infect Dis 1989; 11 Suppl 1:S313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/59\">",
"      Kain KC, Schulzer M, Chow AW. Clinical spectrum of nonmenstrual toxic shock syndrome (TSS): comparison with menstrual TSS by multivariate discriminant analyses. Clin Infect Dis 1993; 16:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/60\">",
"      Davis JP, Osterholm MT, Helms CM, et al. Tri-state toxic-shock syndrome study. II. Clinical and laboratory findings. J Infect Dis 1982; 145:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/61\">",
"      Cone LA, Woodard DR, Byrd RG, et al. A recalcitrant, erythematous, desquamating disorder associated with toxin-producing staphylococci in patients with AIDS. J Infect Dis 1992; 165:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/62\">",
"      Gourley GR, Chesney PJ, Davis JP, Odell GB. Acute cholestasis in patients with toxic- shock syndrome. Gastroenterology 1981; 81:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/63\">",
"      Ishak KG, Rogers WA. Cryptogenic acute cholangitis--association with toxic shock syndrome. Am J Clin Pathol 1981; 76:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/64\">",
"      Centers for Disease Control (CDC). Repeat injuries in an inner city population--Philadelphia, 1987-1988. MMWR Morb Mortal Wkly Rep 1990; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/65\">",
"      Schlievert PM, Kelly JA. Clindamycin-induced suppression of toxic-shock syndrome--associated exotoxin production. J Infect Dis 1984; 149:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/66\">",
"      Stevens DL, Wallace RJ, Hamilton SM, Bryant AE. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis 2006; 42:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/67\">",
"      Edwards-Jones V, Foster HA. The effect of topical antimicrobial agents on the production of toxic shock syndrome toxin-1. J Med Microbiol 1994; 41:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/68\">",
"      Best GK, Scott DF, Kling JM, et al. Protection of rabbits in an infection model of toxic shock syndrome (TSS) by a TSS toxin-1-specific monoclonal antibody. Infect Immun 1988; 56:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/69\">",
"      Bonventre PF, Thompson MR, Adinolfi LE, et al. Neutralization of toxic shock syndrome toxin-1 by monoclonal antibodies in vitro and in vivo. Infect Immun 1988; 56:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/70\">",
"      Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000; 13:602.",
"     </a>",
"    </li>",
"    <li>",
"     Chesney PJ, Davis JP. Toxic shock syndrome. In: Textbook of pediatric infectious diseases, 4th ed, Feigin RD, Cherry JD (Eds), WB Saunders, Philadelphia 1998. p.830.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/72\">",
"      Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992; 267:3315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/73\">",
"      Darenberg J, Ihendyane N, Sj&ouml;lin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/74\">",
"      Darenberg J, S&ouml;derquist B, Normark BH, Norrby-Teglund A. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis 2004; 38:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/75\">",
"      Todd JK, Ressman M, Caston SA, et al. Corticosteroid therapy for patients with toxic shock syndrome. JAMA 1984; 252:3399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/76\">",
"      Larkin SM, Williams DN, Osterholm MT, et al. Toxic shock syndrome: clinical, laboratory, and pathologic findings in nine fatal cases. Ann Intern Med 1982; 96:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/77\">",
"      Paris AL, Herwaldt LA, Blum D, et al. Pathologic findings in twelve fatal cases of toxic shock syndrome. Ann Intern Med 1982; 96:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/52/8010/abstract/78\">",
"      Chuang YY, Huang YC, Lin TY. Toxic shock syndrome in children: epidemiology, pathogenesis, and management. Paediatr Drugs 2005; 7:11.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3161 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_52_8010=[""].join("\n");
var outline_f7_52_8010=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Menstrual cases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonmenstrual",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Methicillin-resistant S. aureus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Toxic shock syndrome toxin-1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Superantigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antibody responses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Skin manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Multiorgan system involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Menstrual versus nonmenstrual cases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Recurrent illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Supportive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Eradication of carrier state",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Additional therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7913091\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3161\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3161|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/23/31103\" title=\"picture 1\">",
"      Rash in Staphylococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/4/29761\" title=\"picture 2\">",
"      Macular erythema in toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/46/37615\" title=\"picture 3\">",
"      Conjunctival suffusion in Staphylococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/25/38290\" title=\"picture 4\">",
"      Desquamation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3161|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/1/35868\" title=\"table 1\">",
"      Clinical criteria for Staphylococcal toxic shock syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=related_link\">",
"      Clinical manifestations and diagnosis of Rocky Mountain spotted fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=related_link\">",
"      Clinical manifestations of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18985?source=related_link\">",
"      Clinical presentation and diagnosis of dengue virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=related_link\">",
"      Differential diagnosis of microbial foodborne disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10263?source=related_link\">",
"      Epidemiology of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28632?source=related_link\">",
"      Epidemiology of and risk factors for Staphylococcus aureus bacteremia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22387?source=related_link\">",
"      Folliculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=related_link\">",
"      Impetigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=related_link\">",
"      Major histocompatibility complex (MHC) structure and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43879?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=related_link\">",
"      Pathophysiology and management of fever in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/10/8361?source=related_link\">",
"      Pathophysiology and treatment of fever in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43831?source=related_link\">",
"      Skin abscesses, furuncles, and carbuncles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=related_link\">",
"      Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8519?source=related_link\">",
"      Treatment of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_52_8011="Attenuation coefficient nodule";
var content_f7_52_8011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relative attenuation coefficients of nodule components (expressed in Hounsfield units, HU)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Air",
"       </td>",
"       <td>",
"        -1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fat",
"       </td>",
"       <td>",
"        -50 to -100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Water",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyst",
"       </td>",
"       <td>",
"        0 to 20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fresh blood clot",
"       </td>",
"       <td>",
"        40 to 60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Noncalcified nodule",
"       </td>",
"       <td>",
"        40 to 160",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcified nodule",
"       </td>",
"       <td>",
"        &gt;200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_52_8011=[""].join("\n");
var outline_f7_52_8011=null;
var title_f7_52_8012="APC initial settings";
var content_f7_52_8012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for the flexible bronchoscope and accessories using argon plasma coagulation*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        APC pulsed effect 1, monopolar non-contact&bull;",
"       </td>",
"       <td class=\"subtitle1\">",
"        APC pulsed effect 2, monopolar non-contact&bull;",
"       </td>",
"       <td class=\"subtitle1\">",
"        APC forced, monopolar non-contact&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"5\">",
"        Argon plasma coagulation",
"       </td>",
"       <td>",
"        - 15 Watts",
"       </td>",
"       <td>",
"        - 15 Watts",
"       </td>",
"       <td>",
"        - 15 Watts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        - Gas 0.3-0.8 l/m",
"       </td>",
"       <td>",
"        - Gas 0.3-0.8 l/m",
"       </td>",
"       <td>",
"        - Gas 0.3-0.8 l/m",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        - Slow pulses",
"       </td>",
"       <td>",
"        - Fast pulses",
"       </td>",
"       <td>",
"        - Continuous output",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        - Deeper coagulation",
"       </td>",
"       <td>",
"        - Superficial coagulation",
"       </td>",
"       <td rowspan=\"2\">",
"        - Superficial to deep thermal insult depending on: a) time/length of activation and b) power setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        - Active regulation (ie, elastic plasma)",
"       </td>",
"       <td>",
"        - Active regulation (ie, elastic plasma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Hemostasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Argon plasma coagulation",
"       </td>",
"       <td>",
"        - 15 Watts (above)",
"       </td>",
"       <td>",
"        - 15 Watts (above)",
"       </td>",
"       <td>",
"        - 15 watts (above)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        - Gas 0.3-0.8 l/m",
"       </td>",
"       <td>",
"        - Gas 0.3-0.8 l/m",
"       </td>",
"       <td>",
"        - Gas 0.3-0.8 l/m",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * This is a synthesis of literature and manufacturer information.",
"     <br>",
"      &bull; Wattage and Gas Flow is recommended as a starting point. Physicians may adjust parameters based upon tissue effect objectives intraoperatively and anatomic presentation pre- and intraoperatively.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Turner, JF, Wang, KP. Endobronchial laser therapy. Clin Chest Med 1999; 20:107. Copyright &copy;1999 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_52_8012=[""].join("\n");
var outline_f7_52_8012=null;
var title_f7_52_8013="Tetanus prophylaxis";
var content_f7_52_8013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Wound management and tetanus prophylaxis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Previous doses of tetanus toxoid*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Clean and minor wound",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        All other wounds",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Tetanus toxoid-containing vaccine",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        Human tetanus immune globulin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Tetanus toxoid-containing vaccine",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        Human tetanus immune globulin",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;3 doses or unknown",
"       </td>",
"       <td>",
"        Yes",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;3 doses",
"       </td>",
"       <td>",
"        Only if last dose given &ge;10 years ago",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Only if last dose given &ge;5 years ago",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Appropriate tetanus prophylaxis should be administered as soon as possible following a wound, but should be given even to patients who present late for medical attention. This is because the incubation period is quite variable; most cases occur within&nbsp;eight days, but the incubation period can be as short as one day or as long as several months.",
"    <div class=\"footnotes\">",
"     * Tetanus toxoid may have been administered as diphtheria-tetanus toxoids adsorbed (DT), diphtheria-tetanus-whole cell pertussis (DTP, DTwP; no longer available in the United States), diphtheria-tetanus-acellular pertussis (DTaP), tetanus-diphtheria toxoids adsorbed (Td), booster tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap), or tetanus toxoid (TT).",
"     <br>",
"      &Delta; Such as, but not limited to, wounds contaminated with dirt, feces, soil, or saliva; puncture wounds; avulsions; wounds resulting from missiles, crushing, burns, or frostbite.",
"      <br>",
"       <font class=\"lozenge\">",
"        &loz;",
"       </font>",
"       The preferred vaccine preparation depends upon the age and vaccination history of the patient:",
"       <br>",
"        <ul>",
"         <li>",
"          &lt;7 years: DTaP.",
"         </li>",
"         <li>",
"          Underimmunized children &ge;7 and &lt;11 years who have not received Tdap previously: Tdap. Children who receive Tdap between age 7 and 11 years do not require revaccination at age 11 years.",
"         </li>",
"         <li>",
"          &ge;11 years: A single dose of Tdap is preferred to Td for all individuals in this age group who have not previously received Tdap.",
"         </li>",
"         <li>",
"          Td is preferred to TT for those who received Tdap previously and when Tdap is not available.",
"         </li>",
"        </ul>",
"        &sect; 250 units intramuscularly at a different site than tetanus toxoid; intravenous immune globulin should be administered if human tetanus immune globulin is not available.",
"        <br>",
"         &yen; The vaccine series should be continued through completion as necessary.",
"         <br>",
"          &Dagger; Booster doses given more frequently than every five years are not needed and can increase adverse effects.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2012. Ann Intern Med 2012; 156:211.",
"       </li>",
"       <li>",
"        Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:13.",
"       </li>",
"       <li>",
"        Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older &mdash; Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2012; 61:468.",
"       </li>",
"      </ol>",
"      <p>",
"       From: American Academy of Pediatrics. Pertussis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. Used with permission of the American Academy of Pediatrics. Copyright &copy; 2012.",
"      </p>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_52_8013=[""].join("\n");
var outline_f7_52_8013=null;
var title_f7_52_8014="rHuTPO intensive chemotherapy";
var content_f7_52_8014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Use of recombinant human thrombopoietin after intensive chemotherapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 277px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with gynecologic malignancy were treated with high dose carboplatin on day 1 alone (red columns) or with carboplatin followed by the daily adminisration of rHuTPO (blue columns). The administration of rHuTPO significantly increased the nadir platelet count, decreased the duration of thrombocytopenia, and reduced the need for platelet transfusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Vadhan-Raj, S, Verschraegen, C, McGarry, L, et al, Blood 1997; 90(Suppl 1):580a.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_52_8014=[""].join("\n");
var outline_f7_52_8014=null;
var title_f7_52_8015="Chondrocalcinosis in HH";
var content_f7_52_8015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Knee chondrocalcinosis in hemochromatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Serial knee radiographs, separated by 11 years, from a patient with hereditary hemochromatosis. During this time there has been progressive chondrocalcinosis without the development of either joint space narrowing or secondary degenerative arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John S Axford, BSc, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_52_8015=[""].join("\n");
var outline_f7_52_8015=null;
